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ABSTRACT 
 
The ARF protein is encoded by the alternative reading frame of the 
INK4a locus, one of the most frequent sites of genetic loss in human cancers. 
The ARF tumor suppressor function, as a sensor of hyper-proliferative stimuli, 
is to restrict cell proliferation through both p53-dependent and independent 
pathways. However, few studies started to address the possibility that ARF 
might promote the survival of subsets of tumors.  
In the past years, intensive studies have been focused not only on ARF 
activation at transcriptional level but also on the mechanisms regulating ARF 
protein turnover. Here we show that p14ARF is a PKC target. In fact, PKC 
activation mediates phosphorylation and stabilization of ARF endogenously 
expressed protein. Moreover, a phosphomimetic ARF mutant accumulates in 
the cytoplasm and, interestingly, despite the ability to stabilize p53 and bind 
MDM2, is not able to efficiently block cell growth in both human and mouse 
cell lines. These data could be interpreted as a way of cancer cells to escape 
ARF surveillance in tumorigenesis, but they might also indicate that ARF 
phosphorylation in tumor cells could be a mean to sustain tumor progression by 
conferring pro-survival properties to the cells. We thus explored the role of 
endogenously expressed ARF protein in some tumor and stabilized cell lines 
by knocking down ARF expression by siRNA. Unspectedly, we observed a 
block of cell proliferation and induction of DAPK mediated p53-dependent 
apoptosis in ARF depleted Hela and HaCat cells. Our results suggest that ARF 
might have a pro-survival role depending on cellular context. 
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1. BACKGROUND 
 
The ARF protein is encoded by the Alternative Reading Frame of 
the INK4a locus, one of the most frequent sites of genetic loss in human 
cancers after p53 locus (Hainaut et al, 1997; Hall and Peters, 1996; Muniz et al, 
2011). 
A direct contribution of ARF to tumor formation has been documented using 
genetic analysis of tumors, molecular and cell biology methods and animal 
models (Muniz et al, 2011; Shimizu et al, 2010).  
It has been reported that ARF-null mice are highly cancer prone. Particularly, 
ARF knock out mice die after 1 year from spontaneous tumor development, 
with a mean survival latency of 38 weeks. Moreover, heterozygous mice also 
develop tumors after a longer latency than ARF-null mice.  
The 43% of tumors observed in ARF-null mice were sarcomas. In particular, a 
malignant osteogenic sarcoma with pulmonary metastasis and an agiogenic 
sarcoma metastatic to the liver were observed. The others tumors observed in 
ARF-null mice were 29% of lymphomas, 17% of carcinomas and 11% of 
gliomas (Kamijo et al, 1999).  
Although alterations of INK4a-ARF locus are not common in humans, they 
were found in roughly 30% of human tumors such as glioblastoma, melanoma, 
pancreatic adenocarcinoma (Maggi et al, 2014; Sharpless and DePinho, 1999; 
Sherr, 1998). In the majority of the cases all three proteins of the INK4b–ARF–
INK4a locus are lost, making difficult to determine their individual roles in 
human tumor suppression. In particular, many mutations within exon 2 that 
affect both ARF and p16Ink4a are found in cancers ((del Arroyo and Peters, 
2005; Gardie et al, 1998; Rizos et al, 2001; Rutter et al, 2003; Zhang and 
Xiong, 1999). However, there are specific examples where only ARF appears 
to be affected in human cancer, and these cases appear to be most common in 
melanoma patients (Randerson-Moor et al, 2001). In addition to melanoma 
cases, nine of fifty glioblastoma patients have a specific deletion of ARF 
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(Nakamura et al, 2001). Furthermore, the ARF promoter contains a CpG 
island, and ARF expression is frequently downregulated by promoter 
methylation (Maggi et al, 2014).  
Taken together, this collective wealth of evidence clearly demonstrates the 
importance of ARF tumor suppression in human cancers. 
In contrast to its oncosuppressive role, there is a significant fraction 
of human tumors (prostate and lymphoma cancers) where ARF is 
overexpressed, suggesting that depending on the cellular context ARF may 
possess a pro-survival function (Basso et al, 2005; Chen et al, 2010; Humbey et 
al, 2008; Xie et al, 2014). In the last few years, in fact, different laboratories 
have started to elucidate this hypothesis by analyzing ARF role in several 
cellular contexts. In particular, it has been reported that loss of p19ARF fails to 
promote prostate cancer driven by loss of Pten (Chen et al, 2009). In fact, the 
histopatological analysis of prostates derived from p19ARF-/-; Pten-/- double 
mutant mice showed a decreased percentage of prostatic intraepithelial 
neoplasia compared to Pten-/- mice. They also observed that ARF pro-survival 
role was cell context specific. In fact, ARF loss in mouse embryo fibroblasts 
resulted in the increase of cell proliferation (Chen et al, 2009). Furthermore, 
ARF silencing in Myc-driven lymphoma cells, containing mutant p53, impedes 
their survival under nutrient-starved condition and their development as tumor 
in xenograft assays (Humbey et al, 2008). All together these observations led to 
the novel hypothesis that ARF might have  tumor-type specific survival 
functions.   
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1.1 THE HUMAN INK4/ARF LOCUS ENCODES p14ARF PROTEIN. 
  
The ARF-INK4a locus located on human chromosome 9q21, 
encodes two completely unrelated proteins, p16INK4a and p14ARF, both 
potent inhibitors of cell proliferation. The mechanism by which these two 
proteins are produced is quite unusual. Each transcripts has a specific 5’ exon, 
E1α or E1β for INK4a and ARF respectively, that are spliced to a common 
exon 2. This exon contains two overlapped ORFs, therefore the two proteins 
encoded share no amino acid sequence identity (Figure 1).   
The alpha transcript, encoding p16INK4a, was the first to be identified, so the 
protein produced by the alternative beta transcript was named ARF, where 
ARF stands for alternative reading frame. In addiction, it has been found by 
charaterization of the region of human chromosome 9 (chromosome 4 in 
mouse) the presence of the INK4b gene (also knows as CDKN2B) that is 
generated from the tandem duplication of INK4 gene and encodes the kinase 
inhibitor p15 INK4b  (Sharpless and DePinho, 1999). Both p16INK4a and p15 INK4b 
proteins interact and inhibit the kinase activity of cyclin dependent kinases 4 
and 6 (CDKs) which in turn affect Rb pathway and led to E2F repression and 
growth arrest.  Moreover, their binding prevents the interaction of the CDKs 4 
and 6 with the D-type cyclins, required for their  catalytic activity and for the 
cell cycle progression from G1 to S phase (Russo et al, 1998; Serrano et al, 
1993; Sherr, 2006). 
The β transcript results in a polypeptide of 132 amino acids and 14 KDa named 
p14ARF. The mouse β mRNA is translated in a 169 amino acids polypeptide 
named p19ARF (19KDa). Both mouse and human ARF regulate the induction 
of cell cycle arrest and/or apoptosis by p53-dependent and independent 
pathways (Ozenne et al, 2010; Sherr, 2006). Mouse and human ARF 
polypeptides are 45% identical through their exon 1β segments and 50% 
identical overall. By comparison, mouse and human INK4a exon 1α segments 
are 72% identical, and the p16INK4a proteins share 65% identity overall 
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(Korgaonkar et al, 2005). 
ARF is an unstructurated protein, highly basic (22% arginine) and highly 
insoluble (DiGiammarino et al, 2001). In addiction, it is well known that ARF 
needs to interact with other proteins to bring its charge to a more neutral pH 
and to explicate its functions (Maggi et al, 2014; Ozenne et al, 2010; Sherr, 
2006).  
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                                                                                                                    Sherr C. J. 2012 
 
Figure 1. View of the INK4-ARF locus.  
The ARF-INK4 locus is located on human chromosome 9q21. 
The alpha transcript consists of exon 1 alpha, exons 2 and 3, and encodes p16INK4a protein. The beta transcript 
generated from an alternative ORF, consists of exon1 beta, exon 2 and exon 3 and encodes p19Arf  protein (p14ARF in 
humans). The INK4b locus encodes p15INK4a protein. The p14 ARF protein inhibits Mdm2 with consequential 
activation of p53. The p15 INK4b and p16INK4a proteins are shown to inhibit CDK4/6 to maintain Rb in its growth-
suppressive mode (Sherr, 2012).  
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1.2 THE ONCOSUPPRESSIVE ROLE OF p14ARF PROTEIN. 
 
One of the most well defined function of ARF protein is to 
suppress aberrant cell growth in response to oncogene insult by activating the 
transcription factor p53 that trigger the expression of many apoptosis inducers 
and cell cycle inhibitory genes (Ozenne et al, 2010).  
P53 mutation is the most frequent genetic alteration in human cancers. In 
particular, it has been shown that overexpression of p53 in both normal and 
neoplastic proliferating cells results in a context-dependent cell cycle arrest or 
apoptosis induction. It is well known that p53, for its important role, is 
subjected to stringent multi-level regulation. It has been widely reported that 
MDM2 interacts with p53, blocks p53-mediated transactivation and targets the 
p53 protein for rapid degradation (Chen et al, 1995; Haupt et al, 1997; 
Kubbutat et al, 1997; Levine, 1997). Pomerantz and collegues (1998) reported 
that p19ARF protein is involved in p53 regulation; in fact, by 
coimmunoprecipitation analisys they found that ARF was able to interact with 
the C-terminal domain of MDM2 and with p53 as a multiprotein complex in 
vivo. In addition to the induction of its transactivation activity, the restoration 
of p53 levels was also observed when ARF was expressed together with p53 
and MDM2. This latter effect was due to, the reduction of the p53 
ubiquitinated forms and thus the reduction of proteasome mediated degradation 
(Pomerantz et al, 1998). By using deletion mutants of ARF protein (able or not 
to localize in the nucleolus) it has been shown that both binding to MDM2 and 
the localization of ARF protein in the nucleolus are necessary for ARF-induced 
p53 stabilization, p53 activation and cell cycle arrest. In particular, the 
interaction between ARF and MDM2 sequestered MDM2 in the granular 
region of the nucleolus, a membrane-less dynamic subnuclear organelle where 
ARF typically resides (Weber et al, 1999). This undeline that the nucleolar 
compartimentalization of the ARF-MDM2 complex is important for the ability 
of both mouse and human ARFs to inhibit the cell cycle progression. This 
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localization depends from the ARF NoLS and from a sequence inside the C-
terminal RING domain of MDM2 that appear unmasked upon ARF binding 
(Weber et al, 2000). In fact, it is known that MDM2 can shuttle between the 
nucleoplasm and the nucleolus in an ARF-dependent manner (Freedman and 
Levine, 1998; Roth et al, 1998; Tao and Levine, 1999). 
Although ARF is undoubtedly a critical component of the p53 
pathway, there are some evidences that ARF has also the ability to restrain cell 
growth independently of p53. Mice lacking ARF, p53 and MDM2 are more 
tumor prone that those lacking only p53 and MDM2. Furthermore, ARF-/- and 
ARF+/- mice develop a broader spectrum of tumors than p53-null mice. In line 
with this Weber and collegues (2000) showed that ARF overexpression can 
induces a G1 arrest in cells lacking p53. In particular, in cells deficient for 
ARF/p53/MDM2 (derived from triple knockout or TKO mice), they observed 
that the reintroduction of wild type ARF was able to prevent S phase entry 
and/or trigger apoptosis by mechanisms that did not require the expression of  
wild-type p53 protein. They also demonstrated a significant reduction of 
colony formation in ARF infected TKO mice. In addiction, it has also been 
reported that p14ARF induces cell cycle arrest in a p53-independent manner in 
human lung tumor cells (Eymin et al, 2003). In particular, p14ARF expression 
determined a G2 arrest followed by apoptosis both in ‘‘in vitro’’ and ‘‘in vivo’’ 
models. In this latter case, upon p14ARF overexpression a decrease of tumor 
growth and induction of lung tumors regression was observed in xenograft 
models.   
Taken together these results support a role of ARF in mediating p53-
independent tumor suppressive functions and suggest that ARF also acts 
independently of the Mdm2-p53 axis in tumor surveillance. 
In line with this, it has been reported that ARF can interacts with a multitude of 
different cellular patners: proteins involved in transcriptional control (E2Fs, 
DP1, p63, c-Myc, Hif1α, nucleolar proteins such as nucleophosmin 
(NPM/B23), viral proteins (HIV-1Tat), mitochondrial protein (p32) and many 
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others other (Figure 2). The variety of the ARF interactors strongly suggested 
that ARF has a wider role to protect the cells upon different types of insults. In 
particular, for some targets, ARF interaction causes alteration of stability. For 
example, B23/NPM and E2F become degraded by the proteasome in an 
ubiquitin-dependent manner, while the CtBP2 antiapoptotic transcriptional co-
repressor and HIV-1 Tat become degraded by the proteasome in a ubiquitin-
independent manner. Other targets change their localization like E2Fs, c-Myc, 
Foxm1B, MDM2, ATR, DP-1, Hif1a upon ARF expression. Only few others, 
like Tip60, Topo I and COMMD1 become activated or stabilized (Pollice et al, 
2008). Moreover, it has been reported that p32 protein, localized in the 
mitochondrial matrix and involved in cellular apoptotic response, is able to 
interact with ARF and to determine ARF’s mitochondrial localization (Itahana 
and Zhang, 2008).  
In addiction, it has been reported from several laboratories that 
ARF is able to promote sumoylation of some of its interactors. Sumoylation is 
a post-translational modification that provide a covalent addiction of the small 
ubiquitin-like modifiers (SUMO1, SUMO2, SUMO3) to ε-amino group of 
lysine residues in the target proteins that have the specific consensus sequence 
ΨKXE (Ψ = hydrophobic amino acid). This modification can affects an high 
variety of phenomena such as protein stability, transport, modulation of gene 
expression (up-regulation or down-regulation), ubiquitination, DNA repair, and 
centromeric chromatid cohesion (Tago et al, 2005). In particular, it has been 
reported that ARF interacts with the Myc-associated zinc finger protein Miz1 
and, by inducing its sumoylation, facilitates the assembly of the Myc-Miz1 
complex that provide to the switch from G1 arrest to apoptosis (Herkert et al, 
2010). Because transcription factors sumoylation can mediate the recruitment 
of coreppressors, they hypothezise that sumoylation of Miz1 enhances 
repression by the Myc-Miz1 complex.  
Moreover, it has been shown that ARF can induce sumoylation of both MDM2 
and nucleophosmin (NPM/B23). It has been demonstrated that this ARF 
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function can be explicated only by direct interaction between ARF and its 
patners, and also in a p53-independent manner (Tago et al, 2005). In line with 
this, it has been shown an increase of sumoylated forms of HDM2, E2F-1, 
HIF-1α, TBP-1 and p120E4F when p14ARF is expressed (Sherr et al, 2005).  
Although the precise mechanism underlying this ARF function is currently 
unknown it has been suggested that ARF explicates this function through a 
direct interaction with the sumo-conjugating enzyme Ubc9. Addictionally, it 
has been reported that ARF also inhibits the function of a de-sumoylating 
protein, SENP3 (Haindl et al, 2008). 
Although ARF involvement in the sumoylation process is well documented, 
the biological meaning of ARF mediated sumoylation is still unclear.  
It has been reported that ARF interacts with p63, a trascription factor involved 
in the development of skin and limb, and induces its sumoylation both in 
HaCat cells (spontaneously immortalized keratinocytes) and in human primary 
keratinocytes. Vivo and collegues (2009) demonstrated that ARF induce p63 
sumoylation and proteasome mediated degradation. In particular, they also 
showed an increase of both ARF and SUMO2/3 protein levels and the 
concomitant decrease of p63 after induction of differentiation program in 
HaCat cells (Vivo et al, 2009). These results suggest that not only ARF-
mediated sumoylation occurring during skin differentiation, but also that ARF 
can restrict cell proliferation in more physiological processes.   
As ARF is mainly localized in the nucleolus this led to the 
hypothesis that it might play a role in the ribosomal biogenesis (Saporita et al, 
2007). ARF implication in these process is still matter of debate. In mammalian 
cells a 47S rRNA precursor transcribed by RNA polymerase I (Pol I) is 
sequentially cleaved to yield the mature 28S and 5.8S rRNAs that form the 
core of the large 60S ribosomal subunit, as well as the 18S rRNA of the smaller 
40S subunit. It has been shown that in ARF inducible cells, the formation of 
28S and 18S rRNA was inhibited upon p19ARF induction (Sugimoto et al, 
2003).   
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Moreover, by using a ChIP approach it has been reported that p14ARF can 
specifically associate with a chromatin fraction that contains the rRNA gene 
promoter suggesting that p14ARF can play a role in modulating rRNA 
transcription (Ayrault et al, 2004).  
Other experimental evidences that confirm a role of ARF in ribosome 
biogenesis derived from the fact that ARF is able to inactivate nucleophosmin 
(NPM), a key player in ribosome biogenesis (Saporita et al, 2007). In fact, 
there are data that show inhibition of rRNA processing following the 
downregulation of NPM mRNA. In addiction, it has been shown by blocking 
NPM nucleo-cytoplasmic shuttling that ARF is able to interfere with the 
ribosome export resulting in a delayed rRNA transcription and processing 
(Sherr, 2006). 
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                                                                                                                        Pollice et al, 2008     
 
Figure 2. Schematic view of ARF binding patners. 
Orange is for partners whose activity is blocked by ARF. Red is for partners that are induced to proteasome and 
ubiquitin dependent degradation by ARF. Pink is for partners that are induced to proteasome and ubiquitinindependent 
degradation by ARF. Green is for partners whose activity or stability are positively regulated by ARF. Blue is for 
partners that regulate ARF protein turnover. A second black circle indicate nucleolar sequestration (Pollice et al, 2008). 
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1.3 ARF AS AN ONCOGENE: A NEW ROLE. 
 
Despite its established role as tumor suppressor, ARF is 
overexpressed in a significant fraction of human tumors (Basso et al, 2005). 
For several years it has been taken for granted that ARF was unfuctional in 
these tumors. Interestingly, Chen and collegues (2009) showed that loss of 
19ARF in prostate ephitelium does not accelerate but rather partially inhibits 
the prostate cancer phenotype of Pten deficient mice. In fact, they reported that 
there was a decrease in the incidence of prostatic intraepithelial neoplasia in the 
ventral prostate of double-null mice (Pten-/- p19ARF-/-) compared with Pten-/- 
mice. Furthermore, using tissue microarrays of human prostate tumor samples 
they found that p14ARF loss was very rare in human prostate cancer and that 
the higher levels of p14ARF were correlated with disease aggressiveness. On 
the other hand, they instead observed an increase in cell proliferation and cell 
trasformation in mouse embryo fibroblasts (MEFs) lacking both Pten and 
p19ARF by using a soft agar trasformation assay.  On the basis of these data 
they concluded that upon Pten loss and p19ARF inactivation there are different 
consequences in prostate cancer and MEFs that are independent of the p53 
pathway and are context dependent (Chen et al, 2009).  
In addiction, last year Xie and collegues (2014) reported that deletion of 
p19ARF remarkably resulted in growth suppression of prostate tumors of 
Pten/Trp53/p19ARF triple knockout mice. They found that ARF was able to 
positively regulate the stability of SLUG, a protein that it is able to promote 
cell migration and cancer metastasis through repression of E-cadherin and the 
regulation of epithelial-mesenchymal transition. In fact, ARF interacts with and 
stabilizes SLUG protein inducing its sumoylation. This would result in an 
increased of prostate cancer progression. Furthermore, by using 
immunohistochemistry staining, they observed that after inactivation of 
p19ARF SLUG levels decreased with the concomitant increase of E-Cadherin 
levels resulting in a reduced rate of prostatic cells proliferation (Xie et al, 
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2014). Moreover, it has been reported indeed from Humbey and collegues 
(2008) that ARF silencing can limit the progression of same tumors such as 
lymphoma. Primary murine B-cell lymphoma cell lines were infected with a 
short hairpin directed against ARF transcript and these cells were used for tail 
vein injection assay in immunocompromised mice. The experiment showed 
that lymphoma development was impaired in mice injected with ARF knock 
down cells compared to the controls  (Humbey et al, 2008). 
These experimental evidences seem to suggest the hypothesis that ARF might 
have pro-survival functions, implying that it may function in both tumor 
suppressive and oncogenic pathways in cancers, depending on the cellular 
context.  
In line with this, it has been reported that, depending on cellular context, ARF 
has also a role in the autophagic process with a pro-survival effect. Autophagy 
is a lysosome-mediated process of self-digestion that occurs during periods of 
nutrient deprivation, when proteins and organelles are degradated and the 
released amino acids are used for the synthesis of essential proteins and ATP to 
improve cell survival (figure 3) (Humbey et al, 2008). Interestingly, several 
laboratories have demonstrated a dual role of autophagy in tumor development 
and progression. In fact, on one hand it has been reported that autophagy is 
required to block lymphoma and liver cancers progression; on the other hand, 
there are some data indicating that established tumor cells use autophagy as a 
crucial survival pathway (Balaburski et al, 2010).  
Regarding ARF involvement in the autophagy process it has been 
reported that, depending on cellular context, ARF expression can have opposite 
effects on this mechanism. It has been shown from Reef and collegues (2006) 
that both mouse and human ARF proteins have a single internal methionine 
residues (Met45 and Met 48, respectively) used as a start point for a different 
translational initiation with the generation of a small mitochondrial ARF 
(smARF). This short form is able to localize to mitochondria although it is well 
known a nucleous/nucleolar localization of the full-lenght ARF protein. In 
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particular, Reef and collegues observed that after p19ARF overexpression there 
was a decrease of cell viability, induction of caspase-independent cell death 
and also increase of the lipidated LC3 (LC3II) levels, a protein commonly used 
as autophagic marker. In fact, upon induction of autophagy, the predominantly 
cytoplasmic LC3 protein, LC3I, is conjugated to phosphatidylethanolamine to 
yield an LC3II form that associates with autophagosomal membranes. 
Furthermore, Reef and collegues found an attenuation of cell death induced by 
smARF overexpression upon Beclin-1 silencing, suggesting a different pro-
death function for this short isoform (Reef et al, 2006). Although smARF can 
activate autophagy, this isoform is very unstable and present at low or 
undetectable endogenous levels. These data raised the question about the role 
of full-lenght ARF protein in autophagy. Recently, it has been demonstrated 
that both transfected full-lenght or nucleolar mutant ARF were able to induce 
cell death and autophagy in HEK 293T cells where p53 is inactive (Abida and 
Gu, 2008). In addiction, Abida and collegues (2008) reported that in U2OS 
cells, where the expression of p14ARF was under control of an IPTG-inducible 
promoter, p14ARF induced autophagy in a p53-dependent manner. 
On the other hand, Humbey and collegues (2008) not only demonstrated that 
the presence of full lenght p19ARF is important for lymphoma development 
but also that, after nutrient deprivation and p19ARF silencing, there was a 
reduction of LC3II protein levels in p53-null MEFs so indicating that 
autophagy pathway is impaired. In line with these findings, Humbey and 
collegues observed not only the accumulation of p62 protein usuallly 
degradated during autophagy but also an impaired cells viability (Humbey et 
al, 2008). Taken together these data suggest that ARF can have a pro-survival 
role in autophagy depending on cellular context. 
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1.4 OTHER FUNCTIONS OF ARF PROTEIN. 
 
Usually, the ARF basal expression levels are low in normal 
proliferating cells suggesting that in this context ARF have no particular 
cellular function.  
Although it is known that ARF protein levels increase after 
oncogenic stimuli, it has been reported that basal ARF has a role in mouse eye 
development. In particular, it has been observed that knockout ARF mice 
developed normally (Kamijo et al, 1999; Kamijo et al, 1997) despite their eyes 
were smaller compared to the eyes of wild type mice (McKeller et al, 2002). 
Moreover, it has been reported that ARF-/- mice display both defects in the 
neuroretina and the lens which ultimately result in blindness. Upon a closer 
examination, it has been demostrated that elements of the hyaloid vascular 
system (HVS) did not regress in ARF-/- mice after post-natal day 10 compared 
to wild type mice where HVS normally regress by post-natal day 14. Loss of 
p53 did not alter the ARF-/- eye phenotype in p53-/- ARF-/- mice. Importantly, 
these charateristics were not observed in p53-/- mice, indicating that ARF role 
in hyaloid vascular regression is p53-independent (Ito and Yoshioka, 1999; 
McKeller et al, 2002).  
In addiction to ARF expression within the eye, ARF has also a role 
in male germ cell development in mouse (Gromley et al, 2009; Zindy et al, 
2003). In fact, it has been reported that ARF is overexpressed in male 
spermatogonia, cells that line the basement membrane of each seminiferous 
tubule. In particular, it has been demonstrated that ARF-/- mice display a 
reduced sperm number compared to wild type mice with increase of p53-
dependent apoptosis during germ cell development (Churchman et al, 2011; 
Cole et al, 2010). 
Furthermore, it has been reported that ARF activity occur also 
during skin differentiation. Vivo and collegues (2009) demonstrated that ARF 
interacts and sumoylates p63 in HaCat cells and in human primary 
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keratinocytes. In particular, it has been reported p63 decrease and ARF 
increase after induction of differentiation program in HaCat cells and in human 
primary keratinocytes (Vivo et al, 2009).  
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                                                                                                            Fleming et., 2011 
 
Figure 3. Schematic view of Authophagy  
Different proteins are involved in the initiation of autophagy which begins with the formation of autophagopore. This 
is followed by the elongation of the double membrane of the vesicle that will become the autophagosome. Once the 
autophagosome fuses with a lysosome an autolysosome is formed were the contents of the vesicle are degrated 
(Fleming et al, 2011). 
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1.5 ARF TURNOVER 
 
When cells are stimulated to proliferate by oncogenic proteins such 
as Myc, E2F, E1A, oncogenic Ras and v-Abl, ARF levels increase (de 
Stanchina et al, 1998; DeGregori et al, 1997; Palmero et al, 1998; Zindy et al, 
1998). After the exposure to some radiations and genotoxic drugs ARF 
expression levels increase contributing to the DNA damage response. 
Moreover, it has been shown that viral infection was able to induce ARF 
expression resulting in reduction of viral infectivity (Garcia et al, 2006; 
Sharpless, 2005; Sherr, 2006). Given its strong ability to block growth and 
proliferation, cells must develop mechanisms that promply reduce either its 
expression or functions when its activity is no longer required. 
Both mouse and human ARF are relatively stable proteins with an 
half-life of about 6 hours in tumor cells, and that its turnover is p53 
independent (Kuo et al, 2004). In particular, it has been shown that ARF 
protein is more stable within the nucleolus and that its half life rapidly decrease 
in the nucleoplasm. This phenomenon could be explained by the fact that in the 
nucleolus ARF protein can interacts with nucleophosmin (NPM/B23) resulting 
in more stable protein complex formation. Furthermore, it has also been 
reported that NPM not only can protects ARF from degradation, but also it is 
important for its nucleolar localization, even though, on the other hand, ARF 
causes NPM polyubiquitination and degradation (Colombo et al, 2006; den 
Besten et al, 2005; Itahana et al, 2003). In this way NPM is able to sequester 
ARF into the nucleolus and to prevent its nucleoplasmic degradation.  
Despite the fact that human p14ARF is a lysine-less protein and the 
murine p19ARF has a single lysine residue not required for proteasome 
degradation, it has been reported that ARF levels increase after treatment of the 
cells with proteasome inhibitors. In particular, Pollice and collegues (2007) 
experiments have shown an increase of ARF protein levels in 293T cells upon 
treatment with the proteasome inhibitor MG132 (Pollice et al, 2007). In 
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general, the fact that ARF levels increase with MG132 treatment suggests that 
ARF degradation depends, at least in part, by the proteasome even if it is well 
known that for the vast majority of proteins, coniugation of ubiquitin to 
internal lysines is the initial event in their degradation by the ubiquitin-
proteasome system (Kuo et al, 2004; Pollice et al, 2004; Pollice et al, 2008; 
Rodway et al, 2004). The proteasome is the site of protein destruction in 
eukaryotic cells and it is composed of the 20S catalytic associate with the 
regulatory 19S subunit. Target proteins that need to be degraded are 
ubiquitinated and then unfolded with consequential translocation into the 
cavity of the catalytic 20S subunit of the proteasome (Hershko and 
Ciechanover, 1998). On the other hand, both 20S subunit and 26S proteasome 
itself are also able to degrade non ubiquitinated proteins even if the mechanism 
is not yet elucidated (Kalejta et al., 2003; Asher et al., 2005). In fact, it is well 
known that proteins such as p21, Hif1α, members of Rb family of tumor 
suppressors, p53 and p73 can be directed and degradated by the proteasome 
without ubiquitination. In many cases, if the protein can be delivered to the 
proteasome in a denaturated or partially unfolded state, ubiquitination should 
not be required for its degradation (Kong et al, 2006; Pollice et al, 2007; Sdek 
et al, 2005). Interestingly, it has been reported that ARF can be degradated in 
vitro by the 20S proteasome in the absence of ubiquitination, and that this 
process can be counteracted by TBP1, Tat Binding Protein 1, a component of 
the regulatory subunit of the proteasome (Pollice et al, 2007). In particular, 
upon ARF-TBP-1 protein interaction, the half-life of ARF protein increased 
(from 6 to 10 hours) with consequential activation of the MDM2/p53 pathway 
(Pollice et al, 2004). 
Neverthless, it has been reported by Kuo et al (2004) that, although 
it lacks Lysine, ARF is subjected to a rare mechanism of ubiquitination that 
takes place at N-terminal of proteins, indipendently of p53 and MDM2 (Kuo et 
al, 2004). All cases of N-terminal ubiquitination have involved mutant proteins 
from which lysine residues were removed by mutation, and the physiologic 
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significance of N-terminal ubiquitination has remained unclear. For example, it 
has been reported that MyoD transcription factor was polyubiquitinated at N-
terminus and degradated by the proteasome (Breitschopf et al, 1998). Another 
case of this rare mechanism it was found to regulate the p21 mutant lysine-less 
turnover (Sheaff et al, 2000). Recently, Chen and collaborators (2010) 
identified a specific ubiquitin ligase for ARF called ULF (ubiquitin ligase for 
ARF) by using a mass spectrometry analysis of the NPM protein complexes. In 
particular, they observed that ARF and ULF interacted both in vivo and in 
vitro. Moreover, upon ULF silencing by RNAi, ARF protein levels increase 
although ARF mRNA levels remained unchanged. In addiction, they showed 
an induction of ARF ubiquitination in a dose-dependent manner upon ULF 
over-expression. Interestingly, they found that proteasome-mediated ARF 
degradation is inhibited in cancer but not in normal cell lines where ARF half 
life is reduced to only 30 minutes. Interestingly, they observed that oncogenic 
stress such as c-Myc expression abrogates ULF-mediated ARF ubiquitination 
by interaction of c-Myc with ULF; this interaction promotes ARF-dependent, 
p53- mediated growth arrest (Chen et al, 2010).  
It is also worth mentioning that it has been very recently reported that MDM2 
intracellular increase can, indeed, cause ARF destruction by the proteasome, 
leading to the hypothesis that in an oncogenic environment in which MDM2 is 
overexpressed, ARF levels are kept low due to a rapid turnover caused by 
MDM2 triggered degradation (Vivo et al 2015). 
Finally, it has been reported that also the Protein Kinase C (PKC) is 
involved in the regulation of ARF stability. Accumulating data suggest that 
various PKC isoforms participate in the regulation of cell proliferation, 
differentiation, survival and death (Nishizuka, 1995). Intracellular and tissue 
distribution together with protein phosphorylation give substrate selectivity to 
these kinases so ensuring a fine tuning of PKC activation. The positive 
correlation between tumor promoting effects of various phorbol esters with 
their ability to activate certain PKC isoforms indicated that PKC activation is a 
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critical step in skin tumor promotion.  
In particular, in a paper published in 2005 from Inoue and Shiraishi it was well 
shown that the α PKC isoform (PKCα) is involved in the stabilization of 
exogenuosly expressed ARF protein level. In fact, they found that after 
activation of PKC by TPA exogenously expressed ARF protein levels were 
stabilized. In addiction, it has been shown that TPA treatment was able to 
stabilize p14 ARF protein in cells expressing a temperature sensitive mutant of 
p53 suggesting that TPA-mediated stabilization of p14ARF protein is p53-
independent (Inoue and Shiraishi, 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   27	  
2. PRELIMINARY DATA AND AIM OF THE STUDY. 
 
In the last years several laboratories, including our, started to 
investigate the mechanisms regulating ARF protein turnover. When I joined 
the Prof. La Mantia lab, dott. M. Vivo had already started to analyze the role of 
Protein Kinase C in the ARF stability regulation.  
Different experiments have revealed an increase of both p14ARF (transcript 
and protein levels) and PKC upon calcium induced keratinocyte differentiation 
(Vivo et al., 2009; Inoue et al., 2005). In addiction, in silico-examination of 
p14ARF protein sequence revealed three potential target sites for 
phosphorylation mediated by PKC. Among the potential PKC target sites 
Threonine at position 8 lies within the most conserved region (amino acids 2-
14) required for the activity and nucleolar localization of ARF protein. 
Preliminary data also showed that ARF wild type was phosphorylated in vitro 
by PKC catalitic subunit. Furthermore, it was demostrated that TPA-induced 
PKC activation results in the stabilization of cytoplasmic ARF. Moreover, in 
various cell lines, p14ARF interacts with PKC (Vivo et al., 2013).  
On the basis of these data, the aim of my study initially was to analize the role 
of phosphorylation on the biological activity, cellular localization and stability 
of ARF protein (Vivo et al., 2013). In addiction, our findings on ARF 
stabilization in the cytosol prompted us to investigate whether the presence of 
ARF in the cytoplasm could results in partially unknown functions. Therefore, 
we decided to examine the role of endogenously expressed ARF protein in 
different cell lines upon its silencing by RNA interference (manuscript in 
preparation).  
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3. MATERIALS AND METHODS 
 
Cell cultures, Cloning, Protein expression and reagents. 
The human epithelial cell line HaCaT was obtained from Dr. 
Antonio Costanzo, Department of Dermatology, University of Rome Tor 
Vergata, 00133 Rome, Italy.  All other cell lines (U2OS, H1299, Hela and 
MCF-7) were purchased from the American Type Culture Collection (ATTC). 
Cells were grown in Dulbecco’s modified Eagle medium supplemented with 
10% fetal bovine serum (Euroclone, Life Science) at 37 °C in a humidified 
atmosphere of 5% (v/v) CO2 in air.  
For DNA transfections the cells were transfected using 
LipofectAMINE 2000 reagent (Invitrogen). For siRNA experiments the cells 
were transfected with RNAi Max reagent (Invitrogen).  
Antibodies used in this study: anti PARP-1 antibody (Beta 
IISer660) (from Cell Signaling Technologies 9542, Boston, MA, USA), anti 
ARF C-18, anti actin I-19, anti p53 DO-1, anti MDM2 SMP-14, (from Santa 
Cruz); anti ARF Ab2 14PO2 (Neomarkers); 6XHIS monoclonal antibody 
(Clontech); anti myc antibody 06549 (Upstate); anti X-press monoclonal 
antibody (Invitrogen); anti pThreonine Q7 (Qiagen); anti-DAPK 5S clone 
(Sigma). 
For cloning of ARF mutants and Western blot (WB) analysis see 
below the attached paper.  
 
Phosphorylation and co-immunoprecipitation assays. 
Immunoprecipitation assay was performed using 4 mg of total 
protein extracts of H1299 treated or not with TPA. The complexes were 
incubated with anti ARF antibody and then, analyzed with SDS-PAGE 
elettrophoresis followed by blotting with anti p-Threonin antibody.  
Co-immunoprecipitation assay was performed using 1 mg of total 
protein extracts of U20S cell line. In particular, the cells were transfected with 
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expression plasmids encoding human MDM2 or Myc tagged p32, and/or X-
press tagged wild type or mutant ARF proteins. Protein extracts were 
immunoprecipitated with anti X-press or anti-ARF antibodies. The complexes 
were blotted and probed with anti-MDM2, anti-Myc and anti ARF antibodies. 
For all the informations about buffers used in these experiments see below the 
attached paper. 
 
Subcellular localization. 
For subcellular localization analysis U2OS cells were plated on 
micro cover glasses and then, transfected with expressing plasmid encoding 
6XHis tagged wild type and mutant ARF.  After 24 hours, the cells were fixed, 
permeabilized and incubated with primary monoclonal antibody against 6XHis 
tag and, then, with anti-mouse as secondary antibody. 100-150 cells were 
analized under a fluorescence microscope and the countes plotted in a graph. 
For informations about statistical analysis see the attached paper. 
 
Protein turn over analysis.  
For protein turnover analysis U2OS cells were plated and, after 24 
hours, treated or not with protein synthesis inhibitor Cycloeximide for 0, 4, 6, 8 
and 10 hours. Total protein extracts were analized with western blot using anti-
ARF and anti-actin antibodies. For information about the concentration of 
inhibitor and antibody used, see the atteched paper. 
 
Proliferation analysis.  
For proliferation analysis U2OS cells were plated in a six well 
multiplates and transfected with plasmids encoding wild type and mutant ARF 
proteins. The cells were treated with G418 for 10 days and then, fixed and 
stained with crystal violet. After 20 minutes, the cells were decolorated and the 
wash solution was used to misure the absorbance. 
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P53 stabilization assay. 
For p53 stabilization assay U2OS cell were transfected with 
increased amount of plasmids encoding wild type and mutant ARF proteins. 
Total protein extracts were analized with western blot using anti-ARF, anti p53 
and anti-actin antibodies. 
For all the informations about plasmid concentrations and antibodies see below 
the attached paper. 
 
siRNA of ARF.  
A duplex siRNA oligomer designed to target ARF was obtained by 
INVITROGEN 
The siRNA sequence for ARF used is : 
• siRNA sens 1 :  GAAGAUCAGGUCAUGAUGA  dTdT.  
• siRNA antisense 1 : UCAUCAUGACCUGAUCUUC  dTdT 
The cells were transfected with siRNA (INVITROGEN) composed by the 
same nucleotides of siARF but in random arrangement (siSCR) as negative 
control. In addiction, a siRNA targeting a sequence firefly luciferase mRNA 
(Quiagen) was used as other negative control. Hela or H1299 or MCF-7 cells 
were transfected with siRNAs (final concentration 50µM) and left for 48 or 72 
hours. Western blots were performed with antibodies directed against ARF, 
PARP-1, actin or GAPDH as loading control. 
 
siRNA of DAPK.  
A duplex siRNA oligomer designed to target DAPK (Quiagen) was 
purchased from Qiagen and used at the final concentration of 50µM. Hela cells 
were silenced for 72 hours and then, analyzed by western blot with antibodies 
directed against ARF, PARP-1, DAPK and actin as loading control.  
 
Treatment with apoptosis inhibitor Z-VAD-fmk. 
After 48 hours of silencing, ARF deplated Hela cells were 
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tripsinizated and replated in presence of Z-VAD-fmk (BioVision) for 5 hours 
(10 mM stock). Z-VAD-fmk is a sinthetic peptide that irreversibly inhibits 
activity of caspase family protease and block apoptosis. Western blot was 
performed with antibodies directed against ARF C-18, PARP-1 and actin as 
loading control.  
 
Light microscopy. 
Hela or H1299 cells were silenced with siRNA directed against 
ARF and negative controls (siLUC or siSCR) for 48 or 72 hours. Then, the 
cells were tripsinizated and replated. The cell shape was analyzed using light 
microscopy at 5 or 8 hours post-replating. The images of light microscopy 
were obtained using the Nikon eclipse TE2000-U microscope at 20X 
magnification. The percentige of cells with round phenotype was reported in a 
graph that represent mean values ± SD of 3 independent experiments. 
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4. RESULTS 
 
4.1 Mutation of Threonine 8 does not affect ARF folding. 
ARF protein sequence has different potential target sites for 
phosphorylation such as Threonine (T8, T31, T73, T95) and Serine (S52, S64, 
S92, S127) residues. In particular, in silico-examination of p14ARF protein 
sequence revealed three potential target sites for phosphorylation mediated by 
PKC. Among the potential target sites for PKC mediated phosphorylation of 
ARF protein, threonine at position 8 lies within the most conserved region 
(amino acids 2-4) required for ARF activity and nucleolar localization (Figure 
4). To understand the role of this residue in ARF function, in our laboratory 
were constructed ARF mutants where threonin 8 was replaced with an alanine 
or an aspartic acid residues, generating mutants that cannot be phosphorylated 
(T8A mutant) or that mimics the phosphorylated status of the protein (T8D 
mutant), respectively. 
In order to verify whether the substitution of threonine 8 could 
have resulted in an uncorrectly folded protein, we decided to test the ability of 
p14ARF mutants (T8A and T8D) to bind two well known ARF partners, such 
as MDM2 and p32, interacting with the ARF N-terminal and C-terminal 
domains respectively (Itahana and Zhang, 2008; Weber et al, 2000).  
To this purpose we performed experiments of co-immunoprecipitation in U20S 
cell lines which express undetectable levels of p14ARF. We transfected U2OS 
cells with expression plasmids encoding human MDM2 in combination or not 
with X-press tagged wild type or mutant ARF. Total protein extracts were 
subjected to immunoprecipitation with antibody directed against the X-press 
tag. Immunoprecipitated complexes were analized by using SDS-PAGE 
elettrophoresis followed by immunoblot with antibodies directed against 
MDM2 and p14ARF. As shown in the input panel in figure 5 (a) (on the left 
side), ARF and MDM2 were efficiently expressed only when transfected. In 
addiction, as reported in the immunoprecipitation panel (on the right in the 
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figure), we were able to see the bands corresponding to both wild type and 
mutants ARF and MDM2 only where cotransfected. These data indicate that 
the substitution of Threonin at position 8 does not affect ARF binding to 
MDM2. 
Then, to verify the correct binding of ARF mutants to p32, we 
decided to transfect U20S cells with expression plasmids encoding Myc tagged 
p32 with wild type or mutants ARF. Immunoprecipitated complexes were 
blotted and probed with anti Myc and p14ARF. In the input in figure 5 (b) we 
were able to see the bands corresponding to p32 and ARF only were 
transfected. In addiction, we obtained a co-immunoprecipitation of both wild 
type and mutant ARF and p32 proteins where co-transfected. Also in this case, 
the experiment showed that T8A and T8D mutant proteins were able to bind 
p32 as wild type ARF protein. 
Taken together these data indicate that both substitutions of threonin 8 do not 
affect ARF binding properties, so suggesting that folding of the protein is not 
compromised by the mutations. 
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                                                                                                                            Vivo et al, 2013. 
Figure 4. Scheme of predicted p14ARF phosphorylation sites. 
Diagramatic scheme of p14ARF phosphorylation sites identified in silico. In light gray is indicated the conserved 2-14 
aminoacid stretch within the N-terminal exon 1β encoded domain (aminoacid 1-65), while in dark gray the exon 2 
nuclear localization signal. PKC phosphorylation sites are shown in bold above the scheme, while other potential 
kinases target sites are denoted in gray below the scheme (Vivo et al, 2013). 
 
 
A) 
 
B) 
                                                                                                                                     
 
                                                                                                                            Vivo et al, 2013. 
 
Figure 5. Mutation of Threonine 8 does not affect ARF binding to MDM2 and p32.  
Co-immunoprecipitation experiments are show in both A) and B) panels. 
A) X-press tagged plasmids encoding ARF mutants or wild type proteins were transfected in U2OS cells in 
combination or not with plasmid encoding human MDM2 protein. Total protein extracts were subjected to 
immunoprecipitation with antibody directed against the X-press tag and analyzed using western blot analysis with anti 
MDM2 and p14ARF antibodies. B) U2OS cells were transfected with plasmid encoding myc tagged p32 in 
combination or not with wild type and mutants ARF. Protein extracts were immunoprecipitated with anti ARF 
antibody followed by immunoblot with anti Myc and ARF antibodies (Vivo et al, 2013). 
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4.2 Mutation of Threonine 8 affects ARF protein turn-over. 
Western blot analysis repeatedly showed that the expression levels of T8A 
mutant was lower compared to T8D mutant and wild type proteins. We thus 
decided to evaluate if the substitution in Threonin 8 could affect the stability of 
ARF protein. 
To this aim, we performed an experiment to measure the half-life of wild type 
and mutant ARF proteins. 
U2OS cells were transfected with expression plasmids encoding ARF wild type 
or mutants. After 24 hours the cells were treated with cycloeximide and 
collected at different time points (0, 4, 6, 8, 10 hours). Total protein extracts 
were blotted and probed with anti ARF and anti ACTIN (as internal control). 
As shown in figure 6 A, the half-life of wild type protein is about 6 hours as 
reported previously (Pollice et al, 2004). T8D mutant showed an half-life 
comparable to wild type protein. In line with its reduced level of expression, 
T8A mutant showed an half-life of about 2 hours after cycloeximide treatment. 
Western blot data were quantified by normalizing band intensities with actin 
protein levels. As shown in the graph reported in figure 6 B, while T8D mutant 
stability is comparable to that of wild type, the half life of T8A mutant is 
strongly reduced. 
Taken together, these data indicate that substitution of Threonin 8 affects the 
half-life of ARF protein and, therefore, that this residue can be involved in the 
regulation of p14ARF stability. 
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A)   
 
                      
  
B) 
             
 
                                                                                                                            Vivo et al, 2013. 
Figure 6. Substitution of Threonin 8 affects p14ARF stability. 
A) U2OS cells were transfected with equal amounts of p14ARF wt, T8A and T8D encoding plasmids and and after 
two days treated with cycloheximide (CHX) for 4, 6, 8, 10 hours. Total protein extracts were analyzed by SDS-PAGE 
followed by immunoblotting with anti ARF and ACTIN antibodies. B) The plot represents half life analysis of wt and 
mutant ARFs. Each profile represents the mean of three independent transfections and WB experiments. Band 
intensities were quantified by Image J analysis and actin normalized before being plotted in graph. The amount of 
protein at different time points is expressed as percentage of total protein, i.e. protein amount at t0. Standard deviations 
are also shown (Vivo et al, 2013). 
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4.3 Mimicking ARF phosphorylation inhibits ARF biological activity. 
Next, we decided to test ARF mutants ability to block cell 
proliferation as wild type protein. We performed Colony Formation Efficiency 
assay (CFE assay) in U20S and NIH 3T3 cells where p53 pathway is intact. 
Cells were transfected with expression plasmids encoding ARF wild type and 
mutants and then  treated with G418 selection for ten days. Subsequently, the 
cells were fixed and coloured by cristal violet and then the colonies counted. 
As reported in figure 7, the experiment showed that T8A mutant, that cannot be 
phosphorylated, was able to block cell proliferation with similar efficiency of 
wild type protein. On the other hand, ectopic expression of T8D mutant that 
mimics the phosphorylated status of the protein was instead, less efficient.  
Next, based on the evidences that ARF overexpression can induce 
cell cycle arrest and/or apoptosis in a p53-dependent manner (Calabro et al, 
1999; Hashemi et al, 2002; Pollice et al, 2004), we decided to verify whether 
substitution at threonine 8 could impair ARF ability to activate p53. U2OS 
cells were transfected with increasing amount of expression plasmids encoding 
wild type or mutant ARF proteins. Total protein extracts were subjected to 
SDS PAGE elettrophoresis followed by immunoblot with an antibody directed 
against p53, ARF and ACTIN (as internal control). As shown in figure 8 both 
T8A and T8D were able to stabilize p53 with similar efficiency of wild type 
protein. These data indicate that substitution of threonin 8 does not affects  
ARF mediated p53 stabilization although both of these mutants showed lower 
expression levels compare to wild type protein. 
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                                                                                                                            Vivo et al, 2013. 
 
Figure 7. Growth suppression by wt and mutant ARF proteins.  
Both graphs indicate ARF and mutants ability to induce growth suppression using a Colony Formation Efficiency 
(CFE) assay. U20S and NIH cells were transfected with the indicated amounts of ARF and mutant expression vectors. 
After selection with G418, colonies were fixed, stained with crystal violet and counted. The plot represents the 
percentage of colonies obtained with the indicated plasmids relative to that detected with the empty vector. Values 
represent the mean of four independent experiments. Standard deviation for each value is also given. Asterisks (*) 
indicate statistically significant differences (p<0.001) for the mutant samples compared to wild type ARF (Vivo et al, 
2013). 
 
 
                              
                                                                                                                            Vivo et al, 2013. 
Figure 8. ARF wild type and mutants mediate p53 stabilization. 
Western blot showing p53 stabilization following ARF (wt and mutant) transfection in U20S cells. U2OS cells were 
transfected with increased amount of plasmids encoding ARF wild type and mutants. Protein extracts were analyzed by 
western blot with anti p53, ARF and ACTIN antibodies (Vivo et al, 2013).  
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4.4 Mimicking Threonine 8 phosphorylation induces ARF accumulation in 
the cytoplasm and nucleus. 
It has been extensively shown that ARF amino acid stretch 2-14 is 
not only involved in MDM2 binding and ARF mediated cell cycle arrest but 
also contribute to p14ARF nucleolar compartimentalization (Weber et al, 2000; 
Pollice et al, 2004). On the basis of this informations, we decided to analyze 
the effect of Threonine 8 substitution on ARF cellular localization. Thus, we 
analysed the effect of T8 mutations on ARF subcellular localization following 
transfections in U2OS cells. 
U2OS cells were transfected with plasmids encoding his tagged wild type or 
mutant ARF and then analized by immunofluorescence assay with anti 
histidine antibody. We counted the number of transfected cells showing 
nuclear, nucleolar and cytoplasmic localization and we reported in a graph the 
percentage of the cells with each distribution pattern. As reported in figure 9, 
90% of cells transfected with wild type ARF showed a nuclear/nucleolar 
localization and only 10% of them a nuclear/cytoplasmic distribution.  
Substitution of threonine 8 with alanine residue did not altered the percentage 
of cells with nuclear/nucleolar localization. In contrast, T8D mutant, where 
threonine 8 was replaced with aspartic acid, showed a consistent increase in the 
percentage of cells with nuclear/cytoplasmic localization. 
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                                                                                                                           Vivo et al, 2013. 
 
Figure 9. Mutations of Threonine 8 change ARF localization.  
U2OS cells were transfected with p14ARF expression plasmid (wt or mutants) and visualized by IF with anti histidine 
antibody. Images were taken with a Nikon fluorescent microscope. The histogram, representing the mean of three 
independent experiments, reports the percentage of transfected cells showing each localization pattern. Standard 
deviations are also shown. Asterisks indicate statistically significant differences between the sample and wt ARF (* = 
p<0.05; ***= p<0.001) (Vivo et al, 2013). 
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4.5 Cytoplasmic localized ARF protein is phosphorylated. 
Experiments of nuclear-cytoplasmic fractionation performed by 
Dott.ssa Maria Vivo revealed that, following treatment with PKC activator 
(TPA), the cytoplasmic pool of ARF increased. In addiction, after lambda 
phosphatase treatment of cytoplasmic extracts, an increase of ARF band 
intensity was specifically observed in treated samples. These data suggested 
that, after phosphatase treatment, multiple phosphorylated ARF species were 
present in the cytoplasm and converged to the 15Kd band.  
We, then, decided to verify whether p14ARF protein could be phosphorylated 
in cell culture. H1299 cells expressing high levels of p14ARF protein, were 
treated with TPA for 2 minutes. Total protein extracts were subjected to 
immunoprecipitation with anti ARF antibody and with IgG as negative control. 
Immunoprecipitated complexes were analyze by SDS PAGE elettrophoresis 
and blotted with an antibody directed against phosphorylated threonine (pThr 
antibody). The experiment shows a 15 KDa band in untreated sample whose 
intensity increases following TPA stimulation (Figure 10 upper panel). Identity 
of this band was confirmed by western blot with anti ARF antibodies (Figure 
10 lower panel). 
Taken together these data confirm that ARF is phosphorylated not only in vitro 
but also in cell culture. 
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                                                                                                                            Vivo et al, 2013. 
Figure 10. ARF is phosphorylated in cell culture. 
ARF is phosphorylated in H1299 cell line. H1299 protein extracts were immunoprecipitated with anti ARF antibody 
and, then, analyzed by western blot analysis using anti p-Threonine antibody (upper panel). In the lower panel is 
shown the efficiency of the immunoprecipitation obteined after stripping and incubation of the membrane with anti 
ARF antibody (Vivo et al, 2013). 
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4.6 ARF loss blocks cell proliferation in both Hela and HaCat cells. 
Our data revealed that a substitution of Threonine 8 mimicking a 
phosphorylated status of ARF protein influences its activity and cellular 
localization. In particular, T8D mutant shows a different cellular localization 
pattern with increased nuclear/cytoplasmic distribution. In addition our data 
seems to point to a p53 independent function of ARF specifically impaired by 
the phosphorylation.  
Our experiments led to the hypothesis that in a tumor environment, where PKC 
is activated, ARF levels increase but its growth inhibitory function might be at 
the same time impaired. Our observations might thus uncover a novel 
mechanism through which cancer cells could escape ARF surveillance during 
cancer progression. Nevertheless, we could suppose that the presence of ARF 
in the cytoplasm could results in partially unknown functions.  Therefore, we 
decided to investigate ARF role in several cancer cell lines. 
To this aim, we performed RNA interfering experiments by using stealth 
siRNA specifically targeting ARF exon 1 beta to have a long lasting depletion 
of our protein. We used Hela cells expressing endogenously ARF protein 
where although not irreversibly, the p53 pathway is disabled due to enhanced 
protein degradation mediated by the viral protein E6 (Johnson et al, 2002; 
Wesierska-Gadek et al, 2002). In line with this, ARF overexpression in these 
cells has no effect on cellular proliferation.  
Hela cells were transfected with siRNA directed against either ARF transcript 
or Luciferase as a negative control. After 6 days, silenced cells were fixed and 
stained with crystal violet and then, the absorbance of the wash used to 
decolorate the cells was misured. As shown in figure 11, in ARF silenced cells 
viability consistently decreased as compared to control siLUCIFERASE 
(siLUC) cells, suggesting that the ARF expression is required to guarantee cell 
proliferation.  
To verify if this effect was cell type specific, we performed the same 
experiment in H1299 lung cancer cells (p14ARF +/+), in breast cancer cells 
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MCF-7 (p14ARF null) as negative control (figure 12) and in immortalized 
HaCat cells where ARF is almost exclusively localized in the cytoplasm (data 
not show).  
Only in HaCat cells ARF loss resulted in decreased viability. These data 
suggest that ARF is not required to guarantee cell proliferation in all the 
cellular contexts. 
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A)                                                                          B) 
 
C) 
                             
 
Figura 12. Growth suppression after ARF silencing in Hela cells. 
A) HeLa cells were transiently transfected with the indicated siRNAs for 5 days, and then cell viability was analysed 
by crystal violet staining (CVS assay). B) Silencing efficiency was analysed by western blot with anti ARF and anti 
actin as loading control. C)The absorbance of each well (NT, siSCR and siARF) was calculated as percentage of the 
control wells (NT) set to 100%. Graphs represent mean values ± SEM of 3 independent experiments.  
 
Figure 12. ARF silencing cells does not affect cell growth in H1299 and MCF-7 cells.  
Cells were transfected with the indicated siRNA and incubated for 6 days and, then, cell viability was analysed by 
CVS assay as described.  
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4.7 ARF loss determines a round phenotype of the cells. 
During our silencing experiments we observed that depleted cells 
were smaller than controls and acquired round phenotype. To get further inside 
this phenomenon, Hela cells were transfected with siRNA directed agaist ARF, 
or luciferase, or with a siRNA composed by the same nucleotides of siARF but 
in random arrangement  (siSCR). After 72 hours of silencing and to follow the 
adhesion process, Hela cells were detached from the plate by tripsinization, 
replated and analized by both western blot and light microscopy at 5 and 24 
hours post-plating. As shown in figure 13 A, 5 hours after replating, control 
cells were almost completely spread. On the other hand, ARF depleted cells 
although adherent to the substrate, showed a round phenotype that become 
more evident at 24 hours post plating when the control cells have completed 
adhesion and spreading processes.  
In parallel, as reported in figure 13 B, we collected cellular protein extracts for 
a western blot analysis and, in line with the previous data, we observed that 
both 5 and 24 hours after replating, ARF  depleted cells showed PARP-1 
cleavage indicating the commitment of apoptotic process. At this point, we also 
performed ARF silencing in H1299 cells where we previosly observed that 
ARF loss did not reduced cell viability (Figure 14). In particular, as shown in 
the western blot analysis (figure 14 A), we did not observe a PARP-1 cleavage 
both 48 and 72 hours after silencing and 8 hours after replating. Neverthless, 
light microscopy images reported in figure 14 B showed the presence of cells 
with a round phenotype in siARF treated cells compared to the controls.  
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A) 
    
 
B) 
                     5 hrs post plating                              24 hrs post plating     
                    
 
Figure 13. p14ARF loss influences cell morphology and apoptosis.  
HeLa cells transiently transfected with the indicated siRNAs for 48h, were detached by trypsinization and replated at a 
density of 1X105/ml in six-well plates. Images were collected by phase-contrast microscope 5 and 24h post plating (A). 
Silencing efficiency and apoptosis were analysed by western blot with anti ARF, anti PARP-1 and anti actin as loading 
control (B). 
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A) 
                   
 
B) 
 
 
Figure 14. ARF silencing determines round phenotype but not PARP-1 cleavage in H1299 
cells.  
H1299 cells were transfected with the indicated siRNA. After 48 and 72 hours from silencing, the cells were detached 
by trypsinization and replated at a density of 1X105/ml in six-well plates. Cells were analyzed by western blot with anti 
ARF and PARP-1 antibodies and actin as loading control (A). Images were collected by phase-contrast microscope 8 
hours post plating (B).  
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4.8 Round phenotype is not apoptosis-dependent. 
On the basis of the fact that ARF silenced Hela cells showed not 
only a round phenotype but also started the apoptosis process, we wondered 
whether these two phenomena were connected or not. To this purpose, Hela 
cells were transfected with siRNA directed agaist ARF or Luciferase (as 
negative control). 48 hours after silencing, the cells were tripsinizated and 
replated in presence of Z-VAD-fmk, which is an apoptosis inhibitor, for 5 
hours. Western blot, reported in figure 15 A, showed that following Z-VAD 
treatment PARP-1 cleavage was inhibited in these experimental conditions. 
Next, we analyzed cell shape by light microscopy and cells treated with Z-
VAD, where apoptotic program was inhibited, still showed the round 
phenotype (Figure 15 B). We reported these results in a graph where we 
compared the number of cells with round phenotype in control and siARF cells 
(Figure 15 C). 
Both these data and the results obtained in H1299 suggest that the round 
morphology of ARF silenced cells was not a consequence of apoptotic program 
engagement. 
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A) 
 
         
 
B)                                                         
                    
C)  
                              
 
Figure 15. ARF silenced cells show round phenotype after inhibition of apoptosis 
mediated by Z-VAD treatment.  
Hela cells were transfected with siARF and siLUC and, after 48 hours, tripsinizated and replated as described. Cells 
were treated with Z-VAD for 5 hours and, then, the cell shape analyze by light microscopy (A) and the number of 
round cells reported in a graph (B). Graphs represent mean values ± SD of 3 independent experiments. Total protein 
extracts were analyzed by western blot with anti ARF and PARP-1 antibodies (C). 
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4.9 ARF loss induces DAP Kinase-dependent apoptosis. 
Experiments performed by Dott.ssa Maria Vivo in Hela cells grown 
in monolayer or in suspension have revealed that, after ARF silencing, only the 
cells in monolayer showed a PARP-1 cleavage suggesting that the 
establishment of cell-matrix engagement is required to induce apoptosis. It has 
been reported that Death Associated Protein Kinase (DAPK) exerts apoptotic 
effects by suppressing integrin functions and integrin-mediated survival 
signals, thereby activating a p53-dependent apoptotic pathway (Wang et al, 
2002). To determine if the observed apoptosis was DAPK dependent, we 
performed ARF depletion experiments in presence or absence of DAP kinase 
expression. Cells were treated with ARF siRNA alone or together with DAP 
kinase specific siRNA in order to simultaneously abrogate both proteins 
expression. Total protein extracts were subjected to SDS-PAGE and blotted 
with anti PARP-1, ARF, DAPK and ACTIN (as loading control). As shown in 
figure 16 A, we observed that PARP-1 cleavage and apoptosis were not 
detected upon simultaneous ARF and DAPK silencing. Taken together these 
data suggest that ARF loss induces DAP Kinase-dependent apoptosis. In line 
with our previous results ARF/DAPK silenced cells show a round phenotype, 
confirming that this cell morphology is not connected with the induction of 
apoptosis program (figure 16 B). 
It has been reported that DAPK can induce apoptosis via p53 
activation (Pei et al, 2014). Thus, we decided to verify p53 status after ARF 
silencing. Hela cells were silenced for 72 hours and then the protein extracts 
analyzed by western blot. As shown in figure 17, we observed an increase of 
p53 total levels in ARF silenced cells suggesting that the DAPK induced 
apoptosis could be p53-dependent. 
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A)  
                
 
B) 
               
 
Figure 16. DAPK response is required for the induction of apotosis but not for the 
acquisition of round phenotype in ARF silenced cells.  
Hela cells were transfected with siARF or siDAPK alone or in combination. After 72 hours, protein extracts were 
analyzed by western blot using anti ARF, PARP-1, DAPK and ACTIN antibodies (A) and cells shape was analyze by 
light microscopy as described (B). Graphs represent mean values ± SD of 3 independent experiments. 
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Figure 17. Effect of ARF silencing on p53 levels.  
Hela cells were transfected with the indicated siRNA and, after 72 hours, protein extracts were analyzed by western 
blot with anti ARF, p53 and PARP-1 antibodies. Actin is a loadin control. 
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5. DISCUSSION. 
 
Mammalian cells that sustain oncogenic insults, after a 
discrimination between physiological and noxious growth promoting states, 
can invoke defensive programmes resulting in a cell cycle arrest and/or 
apoptosis (Sherr, 2006). 
In normal conditions ARF protein is kept at lower levels but, when the cells are 
stimulated to proliferate by oncogenic stimuli, ARF levels increase resulting in 
cell-cycle arrest or apoptosis in a p53-dependent or independent manner. 
(Eymin et al, 2003; Ozenne et al, 2010; Weber et al, 2000). 
Despite its role in growth suppression, ARF is overexpressed in a significant 
fraction of human tumors. Moreover, it has been reported that its silencing can 
limit the progression of same tumors suggesting a possible pro-survival ARF 
function, depending on the cellular context (Chen et al, 2009; Humbey et al, 
2008; Xie et al, 2014).  
On the other hand, ARF can interact with a cohort of different partners and 
become a part of different cellular processes making difficult the formulation 
of a unique ARF role in the cells. 
In the past years, intensive studies have been focused not only on 
ARF activation at transcriptional level but also on the mechanisms regulating 
ARF protein turnover. In fact, it has been demonstrated that ARF degradation 
can be regulated by the proteasome by both ubiquitin independent or lysine-
independent N-terminal ubiquitylation mechanisms (Kuo et al, 2004; Pollice et 
al, 2007). Moreover, it has been observed that in primary cells ARF turnover is 
very fast but, conversely, ARF protein appears to be very stable in cancer cells 
where proteasome degradation is severely impaired (Chen et al, 2010; Kuo et 
al, 2004).  
In this work we provide evidences showing for the first time that 
PKC activation mediates phosphorylation and stabilization of ARF 
endogenously expressed protein. We also showed that an ARF mutant 
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mimicking the phosphorylated status of the protein, despite its ability to 
stabilize p53 and bind to MDM2, is impaired in blocking cell proliferation in 
both human and mouse cell lines. We, thus, identified a novel trascription 
independent mechanism that regulates ARF protein levels both in immortalized 
and cancer cells.  
The hypothesis that ARF activity could be regulated by phosphorylation events 
has been suggested by several and independent observations. The Death 
Associated Protein Kinase (DAPK) is involved in the activation of ARF/p53 
axis (Raveh et al, 2001). Interestingly, it has been described that DAPK is not 
able to induce the increase of p53 and p21 protein levels in p19ARF-/- MEF 
cells, suggesting ARF involvement in this pathway. In addiction, in vitro 
kinase assay showed that p19ARF can be phosphorylated by DAPK but both 
the phosphorylation sites and the physiological relevance of this 
phosphorylation remained unaddressed. DAPK, a calcium/calmodulin (CaM)-
regulated Ser/Thr protein kinase, was originally identified as a factor that 
regulates apoptosis in response to the death-inducing cytokine signal interferon 
γ (INF-γ). In addicion to its well-documented role in the regulation of 
apoptosis, DAPK may also play a role in survival pathways, reflected in its 
activation by growth factor signalling pathways and its ability to counteract 
tumor necrosis factor (TNF)- mediated apoptosis (Jin et al, 2002; Lin et al, 
2010; Stevens et al, 2009).  Furthermore, it has been reported that DAPK also 
has autophagic signalling activity, which can result in both survival or cell 
death (Lin et al, 2010). More recently, the hypothesis of the involvement of 
phosphorylation in controlling ARF activities has also been suggested by di 
Tommaso and collegues (2009). ARF protein sequence has different potential 
target sites for phosphorylation such as Threonine (T8, T31, T73, T95) and 
Serine (S52, S64, S92, S127) residues. It has been reported that, specifically, 
substitution of Thr31 in the T31A mutant severely impaired p14ARF’s ability 
to maintain chromosomal stability in p53-null cells and markedly enhanced its 
stability in p53-positive cells. In addiction, the A41S mutant also displayed an 
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inefficient ability to stabilize p53 and inhibit DNA synthesis despite the same 
or greater expression compared to wild type p14ARF. Although these data 
suggested a potential phosphorylation of ARF protein, the authors were not 
able to confirm this hypothesis after transfection of p14ARF in U2OS cells (di 
Tommaso et al, 2009).  
In addiction to these evidences on ARF potential phosphorylation, our in silico 
examination of p14ARF protein sequence revealed three potential target sites 
for phosphorylation mediated by Protein Kinase C (PKC). In agreement with 
this, our data showed that PKC phosphorylates ARF in vitro and that these two 
proteins interact in different cell lines. Moreover, TPA-induced PKC activation 
resulted in the stabilization of cytoplasmic ARF.  
It has been reported that both activation and downregulation of specific PKC 
isoforms is linked to tumor promotion and progression (Blobe et al, 1994; 
Chen and Mochly-Rosen, 2001; Murriel and Mochly-Rosen, 2003; Ron and 
Kazanietz, 1999). The combined effects of the various PKC isoforms can result 
in diverse conflicting consequences. The final outcome depends on tissue 
specificity, the levels of PKC expression, and the relative contribution of the 
different PKC isoforms in a given cellular context. The involvement of PKC in 
tumor progression has, thus, gained recognition as potential therapeutic targets 
for the treatment of various malignancies. These data are based on the 
observation of xenograft tumor growth inhibition by PKC-alpha knockdown in 
stomach, lung, bladder and colon cancer cell lines (Bosco et al, 2011), and 
increased tumor size from MCF-7 breast cancer cells overexpressing PKC-
alpha, thus indicating a functional requirement for PKCa in tumorigenesis.  
We, thus, decided to analyze the connection between ARF phosphorylation and 
its biological activity and stability. For first we demonstrated that ARF is 
phosphorylated in H1299 cells using immunoprecipitation experiments of ARF 
protein followed by immunoblotting with anti p-Threonine antibody. In 
addition, following TPA treatment we observed an increase of an ARF 
phosphorylated form. These data seem to suggest a role of phosphorylation in 
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the regulation of ARF stability. Interestingly, in line with the observation of di 
Tommaso and collegues (2009), we failed in detecting ARF phosphorylation in 
U2OS cells also upon TPA treatment (unpublished data). This could suggest 
that ARF post transcriptional modification program could depend on the 
cellular context analyzed.  
Among the three potential target sites for PKC mediated phosphorylation , the 
Threonine in position 8 lies within the 2-14 conserved region required for ARF 
biological funtions and for its localization. Therefore, we functionally 
characterized its role in these ARF funtions. We observed that mutation of 
Threonine 8 can influence ARF biological activity, stability and cellular 
localization. In particular the T8A mutant, which cannot be phosphorylated, 
although showing a reduced half-life, retains the same characteristics of the 
wild type protein such as the subcellular localization and the negative control 
of cell proliferation. On the other hand T8D mutant, that mimics a constitutive 
phosphorylated status of the protein, has similar stability of wild type but 
different cellular localization and activity. In fact, T8D has a predominantly 
nuclear/cytoplasmic localization and although it stabilizes p53 and efficiently 
binds MDM2, it is not able to efficiently control cell proliferation. These 
results suggest that the partial loss of function observed with the T8D mutant 
could be ascribed to p53 independent ARF activities specifically impaired by 
the T8D mutation. 
Interestingly, it has been recently shown (Vivo et al, 2015) that mimicking 
ARF phosphorylation impairs MDM2 mediated ARF degradation by the 
proteasome. In addition, MG132 treatment induces ARFT8A accumulation in 
the cytoplasm indicating that the reason why ARF is not usually detectable in 
this subcellular compartment resides in a more rapid turnover.  
These evidences led us to suppose that upon PKC activation, ARF levels 
increase and it localizes prevalently in the cytoplasm where it cannot properly 
explicate its growth inhibitory functions (figure 18).  
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Figure 18. Schematic view of the hypotetic PKC/ARF connection. 
After oncogenic insults PKC is activate and interacts with ARF in the cytoplasm. In this cellular compartment, ARF is 
phosphorylated and stabilized by PKC. This event keeps ARF from entering in the nucleus and inhibiting cell 
proliferation. 
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Increasing phosphorylation could, thus, be a strategy that cells orchestrate to 
promptly escape ARF growth suppression functions either in physiological 
conditions or when cells are forced to proliferate during cancer progression. 
On the other side, these data might also indicate that ARF phosphorylation in 
tumor cells could be a mean to sustain tumor progression by conferring pro-
survival properties to the cells.  
In line with this hypothesis, recently, it has been reported that in cancer cells 
ARF is very stable compared to normal cells. In addiction, it has been observed 
a pro-proliferative ARF role in tumor environment that seem to suggest ARF 
different roles depending on cell context. For example, it has been 
demonstrated that ARF silencing can limit the progression of mouse limphoma 
suggesting its potential pro-survival function (Chen et al, 2009; Humbey et al, 
2008; Xie et al, 2014). Further experiments are needed to clarify the molecular 
mechanisms underlining these observations and their relevance for cancer 
development in vivo.  
In particular, we reasoned that the presence of ARF in the 
cytoplasm could results in partially unknown functions. On this basis we, thus, 
started to investigate ARF’s role in several cell lines performing ARF knock 
down.  In line with this new findings, our data point to a potential pro-survival 
role of ARF in both tumor (Hela) and stabilized cell lines (HaCat).  
We unexpectedly observed loss of viability and induction of apoptosis upon 
ARF silencing both in Hela and HaCat cell lines. In addiction, we observed 
that DAPK is involved in this process. In fact, we obtained a rescue of 
apoptosis upon simultaneous ARF and DAPK silencing in Hela cells. 
Moreover, given that DAPK can induce apoptosis via p53 activation, we also 
analyzed p53 protein levels in ARF depleted Hela cells. Although not 
irreversibly, in these cells the p53 pathway is disable due to enhanced protein 
degradation mediated by the viral protein E6. In line with this, ARF 
overexpression has no effect on cellular proliferation (Wesierska-Gadek et al, 
2002). Neverthless, it has been reported that a de-regulation of PKCδ in 
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cisplatin resistant HeLa cells may allow stabilization of p53 by DNA damage 
(Johnson et al, 2002). Interestingly, we observed an increase of p53 levels, 
suggesting that induction of apoptosis by DAPK could be p53-dependent. In 
agreement with these evidences, we were not able to observe induction of 
apoptosis upon ARF silencing in H1299 where p53 is mutated.  
In line with these data, recent studies showed that ARF in spermatogonia 
facilitates meiotic progression in mice male germ cells. In particular, it has 
been demonstrated that ARF-/- mice display a reduced sperm number 
compared to wild type mice with increase of p53-dependent apoptosis during 
germ cell development. Therefore, ARF expression in spermatogonia instead 
initiates a salutary feed-forward program that prevents p53-dependent 
apoptosis, contributing to the survival of meiotic male germ cells (Churchman 
et al, 2011). 
Interestingly, during ARF silencing experiments we observed that ARF 
depleted cells showed a round phenotype. This phenomenon was not rescued 
after treatment with Z-VAD suggesting that the round morphology of ARF 
silenced cells was not a consequence of apoptotic program engagement.  
This observation opens the way to the novel hypothesis that cytosolic 
(phosphorylated) localized ARF may be involved in cell spreading. In line with 
this hypothesis, unpublished data obtained in our laboratory have revealed that 
ARF interacts and co-localizes with the Focal Adhesion Kinase (FAK), a 
protein tyrosine kinase localized at sites of focal contacts with a role in cell 
spreading and migration. Interestingly, FAK expression and above all its 
phosphorylation on tyrosine 397, has been strongly correlated with tumor 
aggressiveness (Abbi and Guan, 2002). 
One of cancer cell features is the alteration of adhesion process. In 
fact, transformed cells need to loss contact inhibition to growth without 
control. In addiction, alterations in the adhesion pathway can affect cell 
migration. Moreover, both of these processes have a role in the activation of 
metastatic program. Metastasis is one of the clinical parameters with a strong 
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negative influence on the prognosis of cancer patients. Its detection in patients 
is usually associated with resistance to chemotherapeutic treatments and higher 
post-treatment recurrence states. Despite its malignancy the metastatic process 
is highly inefficient, it is estimated that less than 0.5% of cells entering the 
circulatory system form metastasis. Most cells die in non-permissive tissues, 
while others enter a dormant state in the peripheral niche, either at the single 
cell or micro-metastasis stage. When appropriate growth conditions arise, these 
cells exit the dormant state to form metastasis. Some studies suggested that 
autophagy by facilitating tumor dormancy may protect tumor cells from 
anoikis, a programmed cell death that occurs due to the loss of anchorage-
dependent attachment to the extracellular matrix (ECM). Normal cells and 
tissues have low levels of basal autophagy that can dramatically increase upon 
growth factor deprivation, hypoxia, damaging stimuli and proteasome 
inhibition, promoting survival in the vast majority of cases. Recent studies 
have shown that ARF can induce autophagy (Pimkina et al, 2009; Reef et al, 
2006). ARF involvement in autophagy could partly explain why ARF loss in 
some cancerous context can be detrimental for cancer development. 
In addiction, PKC has been implicated as a key molecule involved in cell 
spreading and migration (Timar et al, 1996), in part through interaction with 
beta1-integrins (Parsons et al, 2002). Cellular motility is sustained through 
assembly and disassembly of actin fibers at focal adhesions, whose 
composition and turn over are both controlled by PKC mediated 
phosphorylation (Boeckeler et al, 2010; Ivaska et al, 2005; Ng et al, 1999; 
Rosse et al, 2012). 
Furthermore, it has been reported that DAPK exerts apoptotic effects by 
suppressing integrin functions and integrin-mediated survival signals, thereby 
activating a p53-dependent apoptotic pathway. It has also been observed that 
integrin or FAK activation blocks DAP-kinase–induced upregulation of p53 
(Wang et al, 2002). Moreover, in an experimental metastasis model, the 
expression level of DAP-kinase is inversely correlated with the metastatic 
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activities of the tumors. The re-introduction of DAP-kinase into the highly 
metastatic tumors suppresses their ability to form metastases in mice, implying 
a role of DAP-kinase in anoikis (Inbal et al, 1997). 
Therefore, further experiments will be required to clarify better the 
role of ARF protein in the cytoplasm and the molecular mechanisms 
connecting PKC, ARF and FAK not only in cell cultures but also in human 
tumor samples.  
It will be interesting, also, to investigate the role of FAK in ARF-dependent 
morphology changes, viability and invasion using Hela cells silenced for both 
ARF and FAK. In addiction, it will be intriguing to analyze the time window in 
which ARF expression is required in the acquisition of metastatic phenotype 
using stable ARF depleted inducible cell lines. Furthermore, it would be 
extremely interesting to analyze the effect of ARF depletion both in metastatic 
traits and in tumorigenesis using xenograft experiments. 
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6. CONCLUSIONS. 
 
Collectively, our data suggest that in a tumor environment, after 
PKC activation, ARF protein is stabilized by phosphorylation and accumulates 
in the cytoplasm. In this cellular compartment, phosphorylated ARF is unable 
to efficiently  block cell proliferation.  
These data could be interpreted as a way of cancer cells to escape ARF 
surveillance in tumorigenesis, but they might also indicate that ARF 
phosphorylation in tumor cells could confer a pro-survival properties to the 
cells during cancer progression. 
Experiments still in progress are now exploring the hypothesis that 
through the interaction with un-conventional molecular targets, such as the 
Focal Adhesion Kinase, ARF could mediate cellular response during cancer 
progression ultimately resulting in the regulation of adhesion and spreading. 
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Abstract
The INK4a/ARF locus on the short arm of chromosome 9 is one of the most frequently altered loci in human cancer. It is
generally accepted that ARF is involved in oncogenic checkpoint pathways by sensitizing incipient cancer cells to undergo
growth arrest or apoptosis through both p53-dependent and independent pathways. While intensive studies have been
focused on ARF activation at the transcriptional level, only recently mechanisms governing ARF turnover have been
identified. Here, we show for the first time that p14ARF is a PKC target. Prediction analysis showed many potential
phosphorylation sites in PKC consensus sequences within ARF protein, and, among them, the threonine at position 8 was
the most conserved. Substitution of this threonine influences both ARF stability and localization. Furthermore,
a phosphomimetic ARF mutation reduces the ability to arrest cell growth although the ability to bind MDM2 and stabilize
p53 result unaffected. Thus we propose that phosphorylation of ARF in both immortalized and tumor cell lines could be
a mechanism to escape ARF surveillance following proliferative and oncogenic stress.
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Introduction
The ARF protein is encoded by the alternative reading frame of
the INK4a locus, one of the most frequent sites of genetic loss in
human cancers. Over the last years, a direct contribution of ARF
to tumor formation has been documented using genetic analysis of
tumors, molecular and cell biology methods and animal models
[1,2,3]. Both the human (p14ARF) and mouse (p19ARF) proteins
function as important sensors of hyper-proliferative stimuli acting
to restrict cell proliferation through both p53-dependent and
independent pathways [4,5]. Under normal conditions the p53
protein is kept at low levels by its rapid turn over, and exists in
a latent and inactive form. Activation of p53 in response to cellular
stresses is mediated, at least in part, by inhibition of MDM2
functions [6]. In normal conditions, primary cells contain low
levels of ARF. However, when stimulated to proliferate by
oncogenic proteins such as Myc, E2F, E1A, oncogenic Ras and
v-Abl [7,8,9,10], ARF levels increase. This phenomenon is
generally accompanied by a parallel disruption of the inhibitory
interaction between Mdm2 and p53, resulting in the accumulation
of transcriptionally active p53 that induces specific responses such
as cell-cycle arrest or apoptosis [11,12]. However, genetic analysis
of tumors and the evidence that ARF can induce cell-cycle arrest
in cells lacking Mdm2 and p53 support the notion that ARF might
act independently of MDM2 and p53 [2,5,13,14,15]. Further-
more, the discovery of a plethora of ARF interactors and the
observation that also viral, genotoxic, hypoxic and oxidative
stresses activate an ARF-dependent response, suggest that ARF
has a wider role to protect the cell [16]. Given its strong ability to
block growth and proliferation, cells must develop mechanisms
that promptly reduce either its expression or functions when its
activity is no longer required. While ARF activation, mostly
occurring through transcriptional activation, has been the focus of
intensive studies [17,18,19,20,21] only recently the mechanisms
regulating ARF protein turnover started to be elucidated. ARF
degradation can be regulated by the proteasome by both ubiquitin
independent [22] or lysine-independent N-terminal ubiquitylation
mechanisms [23]. Recently, a specific ARF ubiquitin ligase, ULF
has been identified [23,24]. Moreover, it has been observed that in
primary cells ARF turnover is very fast: these cells express very low
levels of protein, which could be promptly stabilized upon
proteasome inhibitor treatment. Conversely, ARF protein appears
to be very stable in cancer cells where proteasome-mediated ARF
degradation is severely impaired [24].
It has been reported that Protein Kinase C alpha (PKCa) is
involved in the stabilization of exogenously expressed ARF protein
levels [25]. Multiple PKC isoforms have been associated with
epidermal keratinocyte differentiation program and some of them
are activated by calcium [26]. We have previously shown that both
p14ARF transcript and protein levels increase upon calcium-
induced keratinocyte differentiation. Here we present data
showing that endogenous human ARF protein levels increase
following stimuli known to activate the PKC pathway in both
tumor and immortilized keratinocyte cell lines. A careful
examination of ARF protein sequence revealed three potential
PKC phosphorylation sites. Among them, Threonine at position 8
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lies within the most conserved region encompassing amino acids
2–14 and is required for the activity and nuclear localization of
ARF protein [26,27,28]. Our data indicate that mutation of this
residue, mimicking a phosphorylation status of the protein,
influences both ARF activity and cellular localization.
Results
p14ARF Protein Levels Increase following Calcium and
TPA Treatment
We had previously shown that, during calcium induced
differentiation of transformed human keratinocyte cells (HaCaT),
p14ARF increases both at protein and transcriptional levels [29].
To understand if the increase in ARF levels was due to
a transcription independent mechanism, HaCaT cells were
transfected with increasing amounts of a plasmid expressing
p14ARF and treated with 2mM calcium for 12h in presence of
serum. Western blot analysis of total protein extracts (Fig. 1a)
shows that ARF levels increase following stimulation. Quantifica-
tion of multiple esperiments shows a two fold increase of ARF
protein levels following calcium treatment (260,5). It has been
reported that PKCa, which can be activated by Ca2+, is involved
in TPA-mediated stabilization of p14ARF [25]. Thus we analysed
ARF protein levels in HaCaT cells treated with 10mM TPA
(Fig. 1b). The experiment shows that TPA induces a fast PKC
activation, followed by an increase of ARF protein levels after 10
minutes of treatment (2.560,09). Accordingly, a decrease of
almost 70% ARF levels (0,360,05) was obtained when cells were
grown in presence of 5mM bisindolylmaleimide, a known inhibitor
of PKC activation (Fig. 1c). Similar results were obtained using the
p53 deficient human lung cancer cell line H1299 expressing
endogenous ARF (data not shown). Altogether, these experiments
prompted us to further investigate on the potential role of PKC
and phosphorylation on p14ARF regulation.
p14ARF Interacts with and is Phosphorylated by PKC
in vitro
Analysis of ARF protein sequence with GPS 2.1 [30] software
revealed the presence of three potential PKC phosphorylation
sites. Among these, Threonine 8 and Serine 52 lie in the functional
active domain of the protein, while Serine 127 in the C-ter region
of the protein (Fig. 2a). Interestingly, threonine 8 is conserved
among all ARF orthologs. We thus performed an in vitro assay to
test ARF ability to be phosphorylated by PKC. Phosphorylation
assay was performed using a purified MBP::ARF protein and
a commercially available Protein Kinase C phosphorylation assay.
A reaction containing only the maltose binding protein was
performed in parallel, as negative control. Autoradiography
showed a clean phosphorylated MBP-ARF signal, indicating that
ARF is actually a PKC substrate (Fig. 2b, compare lane 2 with
lane 1). A fusion protein in which the three PKC consensus
sequences were simultaneously mutated was used as control. This
mutant was not phosphorylated in these experimental conditions,
thus confirming the specificity of the kinase assay (data not shown).
As many PKC substrates are dephosphorylated by PP1 [31], equal
aliquots of the reaction, after kinase incubation, were subjected or
not to a dephosphorylation assay using the Protein Phosphatase-1
(PP1) catalytic subunit. As shown in Fig2, panel B, the
phosphorylated ARF signal disappeared upon PP1 treatment
(compare lane 4 with lane 3). The ability of PKC to phosphorylate
a p14ARF mutant where the threonine 8 was replaced with an
alanine (MBP::p14ARF T8A) was also analysed. As shown in
Fig. 2c this mutant is still a PKC substrate even if at lesser extent
than the wt protein.
We next verified the physical association between ARF and
PKC by coimmunoprecipitation experiment in H1299 cells
expressing endogenous p14ARF (Fig. 2d). As a negative control
we used the human osteosarcoma U2OS cell line that is wild type
Figure 1. SDS-PAGE analysis of ARF protein levels. a) HaCaT cells were transfected with an empty plasmid (vector) and increasing amount of
p14ARF expression plasmid. Twenty-four hours after transfection cells were treated or not with 2mM Ca2+ as indicated. Cellular extracts were
immunoblotted and analysed with anti His antibody to detect exogenous ARF levels and anti actin as loading control. b) HaCaT cells were treated
with 10mM TPA for different time points. Protein extracts were subjected to WB with anti ARF (C-18) and an anti pPKC pan antibody that recognizes
all the PKC isoforms phosphorylated at a carboxy-terminal residue homologous to serine 660 of PKC b II (activated pPKC). Actin was used as loading
control. c) HaCaT cells were treated with 5mM Bisindolylmaleimide (Bim) for 12 hours (hrs) and analysed with anti ARF and anti actin antibodies.
doi:10.1371/journal.pone.0053631.g001
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for p53 but lacks expression of p16 and p14ARF proteins. Total
extracts were immunoprecipitated with anti ARF antibody and
complexes probed with anti ARF and anti phospho-PKC pan
antibody. Protein complexes were also assayed with an antibody
recognizing a well known ARF protein partner, the MDM2
oncoprotein, as positive control. As shown in Fig. 2 (panel d and e),
a complex between ARF and activated PKC is exclusively
detected in H1299 cells.
Mutation of Threonine 8 does not Affect ARF Folding
The conserved threonine at position 8 lies in a twelve amino
acid stretch (region 2–14, see Fig. 2a) strictly required for ARF
biological activity. To analyse the role of this residue in ARF
functions, we constructed ARF mutants where threonine 8 was
replaced either by an alanine residue, that cannot be phosphor-
ylated (T8A mutant), or by an aspartic acid (T8D mutant) that
mimics the phosphorylated status of the protein. To rule out the
Figure 2. ARF is a substrate of PKC and PP1 in vitro. a) Diagramatic scheme of p14ARF phosphorylation sites identified in silico. In light gray is
indicated the conserved 2–14 aminoacid stretch within the N-terminal exon 1b encoded domain (aminoacid 1–65), while in dark gray the exon 2
nuclear localization signal. PKC phosphorylation sites are shown in bold above the scheme, while other kinases target sites are denoted in gray below
the scheme b) In vitro phosphorylation assay. MBP (lane 1) and MBP::ARF (lane 2) were incubated with labelled cATP and catalytic PKC subunit.
Reactions were then subjected to SDS-page and WB followed by ON exposure (upper panel). The lower panel shows the same filter immunoblotted
with anti MBP antibodies. Detections of MBP::ARF is denoted by (*) on the autoradiograms and WBs. Purified phosphorylated MBP::ARF was divided in
two aliquots and incubated (lane 4) or not (lane 3) with catalytic PP1 and processed as described in a). c) In vitro phosphorylation assay of MBP::T8A
mutant. d) Co-immunoprecipitation of pPKC with ARF: H1299 lysates were incubated with anti-ARF antibody or with mouse IgG as negative control.
Samples were analyzed by immunoblotting with anti pPKC Ser660, anti ARF and anti MDM2 antibodies.
doi:10.1371/journal.pone.0053631.g002
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possibility that the inserted mutations could have resulted in an
uncorrectly folded protein, we tested the binding to MDM2,
interacting with the N-terminal ARF region [28], and to p32 that
binds ARF through the C-terminal domain [32]. U2OS cells were
transfected with expression plasmids encoding human MDM2 or
myc tagged p32, and/or X-press tagged wild type or mutant ARF
proteins (Fig. 3). Immunoprecipitated complexes were blotted and
probed with anti-MDM2, anti- myc and anti-ARF antibodies. The
experiments show that the substitution of threonine at position 8
does not affect ARF binding to MDM2 and p32 (Fig. 3a and b).
Mutation of Threonine 8 Affects ARF Protein Turn-over
Immunoblots of total cell lysates reproducibly showed lower
levels of T8A mutant compared to wt and T8D mutant suggesting
lower protein stability. To explore this possibility, half-life studies
of the wt and mutant proteins were performed using the protein
synthesis inhibitor cycloheximide (Fig. 4). Half-life analyses
showed that reduced expression of T8A mutant correlated with
decreased stability. Wild-type ARF showed a half-life of 6 hours, as
previously reported [33]. While T8D mutant stability is compa-
rable to that of the wt, the half-life of the T8A mutant is reduced to
2 hours, indicating that this residue could be involved in p14ARF
stability (Fig. 4a and 4b).
Mimicking Thr8 Phosphorylation Induces ARF
Accumulation in the Cytoplasm and Nucleus
It has been extensively shown that ARF amino acid stretch 2–14
is not only involved in MDM2 binding and ARF mediated cell
cycle arrest but also contribute to p14ARF nucleolar comparti-
mentalization [28,33]. Thus we analysed the effect of T8
mutations on ARF subcellular localization following transfections
in U2OS cells.
As expected, following transfection wt ARF protein presents
different localization patterns with cells showing three different
stainings: nucleolar (Fig. 5a panel i), nuclear (Fig. 5a panel ii) and
nucleo-cytoplasmic (Fig. 5a panel iii). Quantitation of this result
showed, for the wt protein, a clear nucleolar and nuclear
distribution pattern in the majority of transfected cells (90%),
and a nuclear-cytoplasmic distribution in the remaining 10% of
cells (Fig. 5b). The T to A substitution did not significantly
Figure 3. Mutation of Threonine 8 does not affect ARF folding. a) U2OS cells were transfected with plasmids encoding X-press tagged version
of either wild type or mutants ARF proteins alone or in combination with plasmid encoding human MDM2 protein. Cellular lysates were
immunoprecipitated with anti X-press antibody and samples analyzed by immunoblotting with anti MDM2 and ARF antibodies. b) cells were
trasfected with myc tagged p32 encoding plasmid and wt and mutants ARF as described in a). Cellular lysates were immunoprecipitated with anti
ARF and analysed by IB with anti myc and anti ARF antibodies.
doi:10.1371/journal.pone.0053631.g003
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compromise the number of cells showing a nuclear localization as
shown by quantitation in Fig. 5b. However, replacement of the
same residue with an aspartic acid dramatically reduced the
proportion of cells showing exclusively nucleolar ARF localization
and led to an increase in the percentage of cells with nuclear and
nuclear-cytoplasmic ARF staining (Fig. 5b). Experiments per-
formed with GFP fusion proteins gave similar results (data not
shown). These data suggest that a mutation mimicking T8
phosphorylation can induce accumulation of the protein both in
the cytoplasm and in the nucleus.
Cytoplasmic Localized ARF Protein is Phosphorylated
Endogenous ARF localization was then analysed in tumor
cells such as H1299 by western blot of cytoplasmic and nuclear
extracts. Efficient fractionation was checked with anti PARP-1
for nucleus and anti actin or RACK-1 antibodies for the
cytoplasm as these proteins are mainly enriched in these cellular
compartments (Fig. 6a and [34]). Using different ARF
antibodies, we consistently found an ARF immunoreactive band
both in nuclear and cytoplasmic extracts (Fig. 6a and data not
shown). Moreover, fractionation experiments, performed in the
HaCaT cell line, showed ARF expression almost exclusively in
the cytoplasm (Fig. 6a right panel), in agreement with our
previously published immunofluorescence data [29]. Western
blot analysis also shows that activated PKC is mainly localized
in the cytosol (Fig. 6a).
We next looked at the effect of TPA addition on the ARF
protein levels both in nuclear and cytoplasmic compartments. As
shown in Fig. 6b, following TPA treatment, only the cytoplasmic
pool of ARF increased. Consistently, pPKC appeared upregulated
in the cytoplasm. We thus decided to check the phosphorylation
status of cytoplasmic ARF by a lambda phosphatase treatment
(Fig. 7a). Equal amount of cytoplasmic extracts were incubated or
not with lambda phosphatase and subjected to SDS-page and
western blot with anti ARF antibody. The experiment clearly
shows an increase of the ARF band in the treated sample (compare
lane+with2) in both cell lines and using different ARF antisera
(data not shown).
We next assessed ARF phosphorylation status in H1299 cells
after TPA stimulation using a different approach. Cells were
treated with TPA and protein extracts subjected to immunopre-
cipitation with anti ARF antibody followed by immunoblot with
an antibody directed against phosphorylated threonine (pThr
antibody). The experiment shows a 15 KDa band in untreated
sample whose intensity increases following TPA stimulation
(Fig. 7b upper panel). Identity of this band was confirmed by
western blot with anti ARF antibodies (Fig. 7b lower panel).
Mimicking ARF Phosphorylation Inhibits ARF Biological
Activity
It has been repeatedly shown that ARF ectopic expression
inhibits cell proliferation at least in cells expressing wt p53
[33,35,36]. Wild type and mutant ARF ability to block pro-
liferation was tested by Colony formation efficiency assay (CFE
assay) in U2OS cells where p53 pathway is intact. Results showed
that, although less stable, T8A mutant was able to block cell
proliferation with the same efficiency as the wt (Fig. 8a). Ectopic
expression of the T8D mutant was instead less efficient (60%
residual colonies after G418 selection in T8D versus 30% of wt
and T8A, Fig. 8a). Similar results were obtained in the ARF null
NIH 3T3 mouse cells harbouring wt p53 (Fig. 8a). Interestingly,
western blot assays show that T8D ectopic expression is efficient in
stabilizing p53 (Fig. 8b).
Discussion
In this paper we report data showing that two known inducers
of PKC activation, Ca2+ and TPA, both induce an increase of
p14ARF protein level in immortalized and in tumor cell lines. The
PKC family consists of at least ten serine/threonine kinases
playing a central role in cell proliferation, differentiation, survival
Figure 4. Protein turn-over analysis. a) Half-life analysis of the wt and mutated p14ARF in human U2OS cells. Cells were transfected with p14ARF
wt, T8A and T8D plasmids and treated with cycloheximide (CHX) for the indicated times two days after transfection. ARF and actin levels were
analysed by WB of total extracts. b) The plot represents half-life analysis of wt and mutant ARFs. Band intensities were quantified by Image J analysis
and actin normalized before being plotted in graph. The amount of protein at different time points is expressed as percentage of total protein, i.e.
protein amount at t0. Each profile represents the mean of three independent transfections and WB experiments. Standard deviations are also shown.
doi:10.1371/journal.pone.0053631.g004
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and death [37]. While classical isoforms need both calcium and
the lipid molecules Diacylglycerol (DAG) or phorbol esters (TPA)
for activation, novel kinases are calcium independent and lipid
dependent, while atypical are both calcium and lipid independent.
Our results suggest that the PKC isoform(s) involved might belong
to the classical and/or novel subfamily. Accordingly, the in-
volvement of PKCa in TPA-mediated stabilization of p14ARF has
been reported [25]. PKCa, the major conventional Ca2+ re-
sponsive PKC in epidermis, is highly abundant in skin and is
believed to play a key role in calcium induced keratinocyte
differentiation [38,39]. Remarkably, defective differentiation in
skin cancer correlates with elevated PKCa activity. The positive
correlation between tumor promoting effects of various phorbol
esters with their ability to activate certain PKC isoforms, indicates
that PKC activation is a critical step in skin tumor promotion [40].
Accumulating data show that PKC is linked to promotion and
progression of several tumor types [41,42,43,44] and a number of
pharmacological PKC inhibitors are developed and currently used
in clinical trial. However, PKCs play either as oncogenes or tumor
suppressors in human cancer development [45] and, therefore, the
combined effects of the various PKC isoforms can result in diverse,
conflicting consequences depending on individual isozyme, cell-
type and subcellular localization.
Our findings that ARF is regulated through the activation of
PKC pathway led us to the hypothesis that ARF function might be
regulated by phosphorylation. ARF contains numerous potential
phosphorylation sites, and one study suggested that it could be
a target of death associated protein kinase (DAPK) [46].
Figure 5. ARF localization analysis. U2OS cells were transfected with p14ARF expression plasmids (wt or mutants) and visualized by IF with anti
histidine antibody. Nuclei were stained with DAPI. Images were taken with a Nikon fluorescent microscope. a) Visualization of the three different wt
ARF localization patterns are indicated with i, ii and iii. Scale bar: i, ii = 3mm; iii = 7mm. b) The histogram, representing the mean of three independent
experiments, reports the percentage of transfected cells showing each localization pattern. Standard deviations are also shown. Asterisks indicate
statistically significant differences between the sample and wt ARF (* = p,0.05; *** = p,0.001).
doi:10.1371/journal.pone.0053631.g005
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Moreover, the potential involvement of phosphorylation in
controlling ARF activities has already been suggested by different
experimental approaches [47,48].
Our hypothesis is supported by several findings. First,
sequence prediction analysis shows that three PKC consensus
sequences are present within ARF protein sequence, and
in vitro kinase assay shows that the protein can be specifically
phosphorylated by PKC and dephosphorylated by PP1. In
agreement, a protein complex consisting of activated PKC and
ARF exists in cells, and we observed that immunoprecipitated
ARF can be recognized by a pThr antibody in the H1299 cell
line (Fig. 6b). Moreover, following TPA treatment, the amount
of phosphorylated ARF species increase (Fig. 6b lower panel).
Significantly, TPA-induced PKC activation results in the
stabilization of cytoplasmic ARF.
Furthermore, we have functionally characterized the role of the
conserved threonine 8 that lies within a PKC consensus sequence
in ARF protein. While the T8A mutation does not affect ARF
localization, the phospho-mimetic T8D mutation dramatically
reduces ARF ability to be exclusively localized in the nucleoli
inducing the protein to accumulate in the cytoplasm in a signif-
icative fraction of cells. The observation that l phosphatase
treatment results in a clear thickening of the ARF electrophoretic
band, suggests that the cytoplasmic protein is indeed phosphor-
Figure 6. Sub-cellular fractionaction. H1299 cells, endogenously expressing p14ARF, were subjected to subcellular fractionation. a) Left panel:
cytoplasmic (Cy) and nuclear extracts (Nu) from equal number of cells were subjected to SDS-page and immunoblot with anti PARP-1 (nuclear), actin
and RACK-1 antibodies (cytoplasm), anti pPKC and anti ARF antibodies. Right panel: HaCaT cells were subjected to subcellular fractionation and
analysed as previously described. Histone H1 is a control of nuclear extracts. Cytoplasmic ARF species are indicated by an asterisk (*). b) H1299 cells
were treated with TPA and subsequently subjected to subcellular fractionation. Equal amount of cytoplasmic (left panel) or nuclear (right panel)
extracts were immunoblotted with anti ARF, pPKC, and actin and histone H1 as loading control for cytoplasm and nucleus respectively, as described.
WB shown are representative of at least three independent experiments. Normalized ARF band intensities, shown below each corresponding band,
are expressed as fold enrichment respect to untreated samples arbitrarily set to 1 (see material and methods for details).
doi:10.1371/journal.pone.0053631.g006
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ylated. On the basis of these results we speculate that multiple
phosphorylated ARF species are present in the cytoplasm, and,
after phosphatase treatment, converge to the 15Kd band,
increasing its intensity. Accordingly, the MBPT8A ARF mutant
is still a PKC substrate in vitro (Fig. 2c), suggesting that multiple
sites could be phosphorylated within the endogenous protein, as
indicated by in silico analysis. Finally, while the T8A mutant
retains the ability to inhibit proliferation as the wt protein, the
phosphomimetic mutant T8D is severely impaired in the control
of cell proliferation. Interestingly, both MDM2 binding and p53
stabilization appear to be unaffected by the T8D mutation. These
results are in agreement with the notion that ARF dependent p53
activation takes place in the nucleus [47,49], and suggest that the
partial loss of function observed with the T8D mutant could be
ascribed to p53 independent ARF activities specifically impaired
by the T8D mutation. Our data also suggest that, at least in a p53
plus cell environment, the unphosphorylated protein is active in
blocking cell proliferation.
Analysis of protein turnover shows that the T to A substitution
strongly reduces protein half-life from six to two hours. Despite its
short half-life, T8A retains both nucleolar localization and control
of cell progression abilities. Given that it is expressed at very low
levels respect to the wt protein, the experiments indicate that few
active ARF molecules can guarantee an efficient control of cell
proliferation [50,51].
Altogether our data suggest that, following activation of PKC,
ARF protein is phosphorylated and accumulates in the cytoplasm
where it is unable to efficiently control cell proliferation. Further
experiments are needed to precisely identify the molecular
pathway, the potential involvement of additional kinase/s and
the ARF residues directly involved in this mechanism.
In conclusion we suggest that in a tumor environment, where
PKC is activated, ARF levels increase but its growth inhibitory
Figure 7. ARF phosphorylation assays. a) l phosphatase assay: equal amount of HaCaT and H1299 cytoplasmic extracts were incubated (lane 2
and 4) or not (lane 1 and 3) with l protein phosphatase (l PPase), analysed by high resolving SDS-PAGE and blotted with anti ARF antibody. Actin is
a loading control, while anti pAKT immunoblot is a reaction control. ARF band intensities, quantified as previously described, are also given. b)
Immunoprecipitation: H1299 cells treated or not with TPA were immunoprecipitated with anti ARF antibody, subjected to SDS-page and blotted with
anti pThr antibody (upper panel). The filter was stripped and incubated with anti ARF antibody (lower panel).
doi:10.1371/journal.pone.0053631.g007
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function is impaired. Interestingly, despite its role in growth
suppression, ARF is overexpressed in a significant fraction of
human tumors [52]. These observations, together with our
findings underscore the need for a careful re-evaluation of the
status and role of p14ARF in human cancer.
Our observations uncover a novel mechanism through which
cancer cells might escape ARF surveillance during cancer
progression. A deeper understanding of the PKC dependent
ARF functions may provide previously unknown and critical
therapeutic targets for cancer treatment.
Materials and Methods
Cell Culture, Cloning, Protein Expression and Reagents
The human epithelial cell line HaCaT was obtained from Dr.
Antonio Costanzo, Department of Dermatology, University of
Rome Tor Vergata, 00133 Rome, Italy. All other cell lines
(U2OS and H1299) were purchased from the American Type
Culture Collection (ATTC). Cells were grown in Dulbecco’s
modified Eagle medium supplemented with 10% fetal bovine
serum (Euroclone, Life Science) at 37uC in a humidified
atmosphere of 5% (v/v) CO2 in air. Cells were transfected
using LipofectAMINE 2000 reagent (Invitrogen). For CFE
Figure 8. Growth suppression by wt and mutant ARF proteins. a) Graph indicating ARF and mutants ability to inhibit cell proliferation. U2OS
and NIH cells were transfected with the indicated amounts of ARF and mutant expression vectors. After two weeks selection to isolate transfected
colonies, cells were fixed and stained with crystal violet. The plot represents the percentage of colonies obtained with the indicated plasmids relative
to that detected with the empty vector. Values represent the mean of four independent experiments. Standard deviation for each value is also given.
Asterisks (*) indicate statistically significant differences (p,0.001) for the mutant samples compared to wt ARF. b) Western blot showing p53
stabilization following ARF (wt and mutant) transfection in U20S cells.
doi:10.1371/journal.pone.0053631.g008
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analysis U2OS were trasfected with calcium phosphate pre-
cipitation as previously described [53].
The T8 amino acid changes were inserted into human p14ARF
by site-directed mutagenesis using a wild-type p14ARF cDNA
template. Standard polymerase chain (PCR) reaction conditions
were used with each set of primers containing the desired
mutations, and all products were verified by sequencing before
subcloning into pMal, pcDNA3.1 and pEGFP vectors.
Antibodies used in this study: anti PARP-1 and anti-phospho-
PKC (pan) antibody (Beta IISer660) (from Cell Signaling
Technologies 9542, Boston, MA, USA); anti RACK-1 B3, anti
ARF C-18, anti actin I-19, Anti HistoneH1 N-16, anti p53 DO-1,
anti MDM2 SMP-14, (from Santa Cruz); anti ARF 4C6/4
(Abcam); anti ARF Ab2 14PO2 (Neomarkers); 6XHIS mono-
clonal antibody (Clontech); anti myc antibody 06549 (Upstate);
anti X-press monoclonal antibody (Invitrogen); anti pThreonine
Q7 (Qiagen). Western blot (WB) analysis was performed as
previously described [29]. The molecular weight marker used for
SDS page is the PageRulerTM Prestained Protein Ladder
(Fermentas and Pierce). Extracts were blotted onto PVDF
Immobilon-P transfer membrane (Millipore cat. NO.
IPVH00010). Proteins were visualized with an enhanced chemi-
luminescence detection system (Amersham ECLplus TM) and
images were taken with ChemiDoc XRS System (Bio-Rad
Laboratories) and analysed with the QuantityONE software
except when differently indicated.
Reagents used in this study: TPA was purchased from
Applichem, Cycloheximide and Bisindolylmaleimide from Cal-
biochem. TPA and cycloheximide were dissolved in DMSO and
used at 10mM and 80 mg per ml respectively. Bisindolylmaleimide
(Bim) was used at 5mM final concentration. ARF band intensities
following various treatments (Fig. 1–6–7) were quantified,
normalized to actin (or to histone H1 in case of nuclear extracts
in fig. 6) and reported as fold increase or decrease compared to
untreated sample. Each value represents the mean of three
independent experiments 6 standard deviations.
Protein Turnover Analysis
For half-life studies, transfected U20S were replated onto 6-well
dishes, allowed to adhere overnight, and treated with cyclohex-
imide or left untreated (0 hour control) for various time points.
Cells were harvested and p14ARF protein levels examined by WB
analyses of whole cell lysates with anti ARF antibody (C-18, Santa
Cruz) and actin as loading control. Band intensities at the different
time points were quantified by Image J Software, normalized to
actin and reported in graph as percentage of total protein (protein
a t0). Each profile represents the mean of three independent
experiments. Standard deviations are also shown.
Subcellular Localization Assay
U2OS cells (5.06104) were plated in 35 mm dish on micro
cover glasses (BDH) and transfected with 0.5mg of plasmid
expressing wt or mutant ARF. At 24 hrs after transfection with
the indicated vectors, cells were washed with cold phosphate-
buffered saline (PBS) and fixed with 4% paraformaldehyde
(Sigma-Aldrich, Germany) for 15 min at RT. Cells were
permeabilized with ice cold 0.5% Triton X-100 for 5 min and
then washed with PBS. Subcellular localization were determined
by using the monoclonal antibody against 6XHis, 1h a RT,
followed by incubation with a Cy3-conjugated anti-mouse
antibody (ImmunoResearch Laboratory) at 37uC for 30 min.
After PBS/0.05% Tween washing, the cells were incubated with
DAPI (Sigma-Aldrich, Germany) for 3 min and washed with PBS/
0.05% Tween. Coverslip were mounted with Vectashield
(VectorLab) and examined under a fluorescence microscope
(Nikon). For each transfection point, subcellular localizations were
analysed in 100–150 cells and results plotted in graph. Histograms
(% of transfected cell 6 S.D.) represent the mean of at least three
independent transfection experiments. Statistical analysis of
variance (Anova plus Bonferroni post test) was performed using
GraphPad Prism 5.0 software.
Subcellular fractionation of H1299 and HaCaT cells was
carried out as by Colucci-D’Amato et al., 2000 [54] with minor
modifications. In order to analyse ARF protein distribution in the
nuclear and cytoplasmic compartments, same number of cells and
nuclei were processed as described. Cells were harvested, washed
in ice cold PBS, resuspended in hypotonic buffer (Hepes 10mM,
KCl 60mM, DTT 1mM plus protease inhibitors) and incubated
on ice for 20 minutes. Following addition of NP-40 (0.2% final
concentration) cells were further incubated 1 minute on ice and
spun at 600g for 5 minutes. Supernatants were subsequently
centrifuged at 13000 rpm for 15 min to pellet unbroken nuclei
and organelles to obtain clear cytoplasmic lysates. Nuclei were
briefly washed in hypotonic buffer to eliminate traces of detergent,
purified on sucrose cushion, counted and lysed in RIPA buffer. To
verify the purity of the subcellular fractionation, anti-PARP1, anti
Histone H1, anti-rack1 and anti actin antibodies have been used in
WB.
Proliferation Assay
For the CFE assay (colony formation efficiency assay) U2OS
(16105 cells per well) cells were seeded into 6-well multiplates,
transfected with 2 mg of total plasmid DNA using the standard
calcium phosphate method and processed as previously described
[53]. Graphs (% of remaining colonies6 S.D.) represent the mean
of at least four experiments. Statistical analysis of variance was
performed as previously described.
p53 Stabilization Assays
Stabilization of p53 was performed in U2OS transfected with
wt, T8A and T8D mutant plasmid constructs. Protein levels were
analysed 24h after transfection with anti ARF (C-18), anti p53
(DO-1) and anti actin antibody as loading control.
Phosphorylation Assays
The MBP::ARF fusion proteins (both wt and mutants) were
obtained as previously described [53] and subjected to an in vitro
phosphorylation assay using a commercially available kit following
manufacturer instructions (Stratagene). PP1 dephosphorylation
assay was performed with the catalytic PP1 subunit (Promega)
following manufacturer instructions.
Lambda-phosphatase (l-PPase; New England Biolabs) treat-
ment was performed as previously described [55]. Immunopre-
cipitation following TPA treatment: 4 mg of total cellular extracts
of H1299 cells treated or not with TPA (10mM for 2 min) were
lysed in IP buffer (Tris-HCl pH7 10mM, NaCl 150 mM, SDS
0.1%, Triton-X100 1%, EDTA 1mM, EGTA 0,5mM) plus
protein phosphatase inhibitors. Cleared lysates were incubated
with 3mg of anti ARF (Ab2 14PO2, Neomarkers) ON. After
washing immunocomplexes were subjected to SDS-page on a 13%
gel followed by incubation with anti pThreonine (1:100 dilution in
3%BSA) followed by chemioluminesce (Pierce). The filter was then
stripped and incubated with anti ARF antibody (C-18) in order to
visualize total immunoprecipitated ARF protein.
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Co-Immunoprecipitation
ARF/pPKC co-immunoprecipitation assay were performed
with 2 mg of total cellular extracts. Cells were harvested, lysed
with co-ip buffer (Tris-HCl pH7 10mM, NaCl 150 mM, NP40
0.5%, glycerol 10%, EDTA 0.5mM) and incubated ON with anti
ARF antibody (C-18 Santa Cruz). After washing immunocom-
plexes were subjected to WB and analysis with anti pPKC pan
antibody (Beta IISer660, Cell Signalling), anti ARF (Ab2 14PO2,
Neomarkers) antibody and anti MDM2 antibody.
ARF (wild type and mutants)/MDM2 or myc tagged p32 co-
immunoprecipitation assays were performed with 1 mg of total
cellular extracts. Twenty-four hours following transfection cells
were harvested and processed as described. Ip were carried out
with anti X-press antibody and immunoprecipitated samples
analysed by WB with anti MDM2, anti myc and anti ARF
antibodies.
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